BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Heinemann V, Boeck S, Hinke A, Labianca R, Louvet C. Meta-analysis of randomized trials: evaluation of benefit from gemcitabine-based combination chemotherapy applied in advanced pancreatic cancer. BMC Cancer 2008;8:82. [PMID: 18373843 DOI: 10.1186/1471-2407-8-82] [Cited by in Crossref: 280] [Cited by in F6Publishing: 265] [Article Influence: 20.0] [Reference Citation Analysis]
Number Citing Articles
1 Conroy T, Bachet JB, Ayav A, Huguet F, Lambert A, Caramella C, Maréchal R, Van Laethem JL, Ducreux M. Current standards and new innovative approaches for treatment of pancreatic cancer. Eur J Cancer. 2016;57:10-22. [PMID: 26851397 DOI: 10.1016/j.ejca.2015.12.026] [Cited by in Crossref: 85] [Cited by in F6Publishing: 86] [Article Influence: 14.2] [Reference Citation Analysis]
2 Imamura T, Komatsu S, Ichikawa D, Kawaguchi T, Miyamae M, Okajima W, Ohashi T, Arita T, Konishi H, Shiozaki A, Morimura R, Ikoma H, Okamoto K, Otsuji E. Liquid biopsy in patients with pancreatic cancer: Circulating tumor cells and cell-free nucleic acids. World J Gastroenterol 2016; 22(25): 5627-5641 [PMID: 27433079 DOI: 10.3748/wjg.v22.i25.5627] [Cited by in CrossRef: 41] [Cited by in F6Publishing: 37] [Article Influence: 6.8] [Reference Citation Analysis]
3 Hagmann W, Faissner R, Schnölzer M, Löhr M, Jesnowski R. Membrane drug transporters and chemoresistance in human pancreatic carcinoma. Cancers (Basel) 2010;3:106-25. [PMID: 24212609 DOI: 10.3390/cancers3010106] [Cited by in Crossref: 27] [Cited by in F6Publishing: 20] [Article Influence: 2.3] [Reference Citation Analysis]
4 Bruera G, Massacese S, Candria S, Galvano A, Manetta R, Giordano AV, Carducci S, Di Sibio A, Ciacco E, Russo A, Ricevuto E; Oncology Network ASL1 Abruzzo, Italy. Real life triplet FIr/FOx chemotherapy in first-line metastatic pancreatic ductal adenocarcinoma patients: recommended schedule for expected activity and safety and phase II study. Oncotarget 2018;9:31861-76. [PMID: 30159128 DOI: 10.18632/oncotarget.25870] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
5 Huang P, Zhong XY, Xu Y, Cui YF. Role of neoadjuvant therapy and adjuvant therapy in treatment of pancreatic cancer. Shijie Huaren Xiaohua Zazhi 2013; 21(14): 1292-1296 [DOI: 10.11569/wcjd.v21.i14.1292] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
6 Conroy T, Gavoille C, Samalin E, Ychou M, Ducreux M. The role of the FOLFIRINOX regimen for advanced pancreatic cancer. Curr Oncol Rep. 2013;15:182-189. [PMID: 23341367 DOI: 10.1007/s11912-012-0290-4] [Cited by in Crossref: 55] [Cited by in F6Publishing: 48] [Article Influence: 6.1] [Reference Citation Analysis]
7 Sohn BS, Yuh YJ, Song HS, Kim BS, Lee KH, Jang JS, Kim SR. Triplet cytotoxic chemotherapy with gemcitabine, 5-fluorouracil and cisplatin for advanced pancreatic cancer. Oncol Lett 2015;10:1204-10. [PMID: 26622653 DOI: 10.3892/ol.2015.3347] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
8 Wilkowski R, Boeck S, Ostermaier S, Sauer R, Herbst M, Fietkau R, Flentje M, Miethe S, Boettcher HD, Scholten T, Bruns CJ, Rau HG, Hinke A, Heinemann V. Chemoradiotherapy with concurrent gemcitabine and cisplatin with or without sequential chemotherapy with gemcitabine/cisplatin vs chemoradiotherapy with concurrent 5-fluorouracil in patients with locally advanced pancreatic cancer--a multi-centre randomised phase II study. Br J Cancer 2009;101:1853-9. [PMID: 19904268 DOI: 10.1038/sj.bjc.6605420] [Cited by in Crossref: 44] [Cited by in F6Publishing: 33] [Article Influence: 3.4] [Reference Citation Analysis]
9 Lee JK, Ryu JK, Yang KY, Woo SM, Park JK, Yoon WJ, Lee SH, Jeong KS, Kim YT, Yoon YB. Effects and mechanisms of the combination of suberoylanilide hydroxamic acid and bortezomib on the anticancer property of gemcitabine in pancreatic cancer. Pancreas. 2011;40:966-973. [PMID: 21487323 DOI: 10.1097/mpa.0b013e3182156d5a] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
10 Ito T, Takada R, Omoto S, Tsuda M, Masuda D, Kato H, Matsumoto T, Moriyama I, Okabe Y, Shiomi H, Ishida E, Hatamaru K, Hashimoto S, Tanaka K, Kawamoto H, Yanagisawa A, Katayama T, Yazumi S; Biliopancreatic Study Group. Analysis of Prognostic Factors in Pancreatic Metastases: A Multicenter Retrospective Analysis. Pancreas 2018;47:1033-9. [PMID: 30048381 DOI: 10.1097/MPA.0000000000001132] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
11 Tummers WS, Miller SE, Teraphongphom NT, Gomez A, Steinberg I, Huland DM, Hong S, Kothapalli SR, Hasan A, Ertsey R, Bonsing BA, Vahrmeijer AL, Swijnenburg RJ, Longacre TA, Fisher GA, Gambhir SS, Poultsides GA, Rosenthal EL. Intraoperative Pancreatic Cancer Detection using Tumor-Specific Multimodality Molecular Imaging. Ann Surg Oncol 2018;25:1880-8. [PMID: 29667116 DOI: 10.1245/s10434-018-6453-2] [Cited by in Crossref: 68] [Cited by in F6Publishing: 60] [Article Influence: 17.0] [Reference Citation Analysis]
12 Tschoep-Lechner KE, Milani V, Berger F, Dieterle N, Abdel-Rahman S, Salat C, Issels RD. Gemcitabine and cisplatin combined with regional hyperthermia as second-line treatment in patients with gemcitabine-refractory advanced pancreatic cancer. Int J Hyperthermia. 2013;29:8-16. [PMID: 23245336 DOI: 10.3109/02656736.2012.740764] [Cited by in Crossref: 28] [Cited by in F6Publishing: 27] [Article Influence: 2.8] [Reference Citation Analysis]
13 Hashimoto A, Tanaka T, Sho M, Nishiofuku H, Masada T, Sato T, Marugami N, Anai H, Sakaguchi H, Kanno M, Tamamoto T, Hasegawa M, Nakajima Y, Kichikawa K. Adjuvant Hepatic Arterial Infusion Chemotherapy After Resection for Pancreatic Cancer Using Coaxial Catheter-Port System Compared with Conventional System. Cardiovasc Intervent Radiol 2016;39:831-9. [PMID: 26762632 DOI: 10.1007/s00270-016-1292-7] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
14 Fristedt R, Elebro J, Gaber A, Jonsson L, Heby M, Yudina Y, Nodin B, Uhlén M, Eberhard J, Jirström K. Reduced expression of the polymeric immunoglobulin receptor in pancreatic and periampullary adenocarcinoma signifies tumour progression and poor prognosis. PLoS One 2014;9:e112728. [PMID: 25397670 DOI: 10.1371/journal.pone.0112728] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.8] [Reference Citation Analysis]
15 Wolfgang CL, Herman JM, Laheru DA, Klein AP, Erdek MA, Fishman EK, Hruban RH. Recent progress in pancreatic cancer. CA Cancer J Clin. 2013;63:318-348. [PMID: 23856911 DOI: 10.3322/caac.21190] [Cited by in Crossref: 479] [Cited by in F6Publishing: 473] [Article Influence: 53.2] [Reference Citation Analysis]
16 Xin Y, Shen XD, Cheng L, Hong DF, Chen B. Perifosine inhibits S6K1-Gli1 signaling and enhances gemcitabine-induced anti-pancreatic cancer efficiency. Cancer Chemother Pharmacol. 2014;73:711-719. [PMID: 24519751 DOI: 10.1007/s00280-014-2397-9] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 2.6] [Reference Citation Analysis]
17 Matsumoto K, Miyake Y, Kato H, Kawamoto H, Imagawa A, Toyokawa T, Nakatsu M, Ando M, Hirohata M, Yamamoto K. Effect of Low-Dose Gemcitabine on Unresectable Pancreatic Cancer in Elderly Patients. Digestion 2011;84:230-5. [DOI: 10.1159/000330384] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
18 Saletti P, Sessa C, De Dosso S, Cerny T, Renggli V, Koeberle D. Phase I dose-finding study of vandetanib in combination with gemcitabine in locally advanced unresectable or metastatic pancreatic adenocarcinoma. Oncology 2011;81:50-4. [PMID: 21921646 DOI: 10.1159/000330769] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
19 Laquente B, Lopez-Martin J, Richards D, Illerhaus G, Chang DZ, Kim G, Stella P, Richel D, Szcylik C, Cascinu S, Frassineti GL, Ciuleanu T, Hurt K, Hynes S, Lin J, Lin AB, Von Hoff D, Calvo E. A phase II study to evaluate LY2603618 in combination with gemcitabine in pancreatic cancer patients. BMC Cancer 2017;17:137. [PMID: 28202004 DOI: 10.1186/s12885-017-3131-x] [Cited by in Crossref: 29] [Cited by in F6Publishing: 24] [Article Influence: 5.8] [Reference Citation Analysis]
20 Vincent A, Herman J, Schulick R, Hruban RH, Goggins M. Pancreatic cancer. Lancet. 2011;378:607-620. [PMID: 21620466 DOI: 10.1016/so140-6736(10)62307-0] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
21 Ko AH, Truong TG, Kantoff E, Jones KA, Dito E, Ong A, Tempero MA. A phase I trial of nab-paclitaxel, gemcitabine, and capecitabine for metastatic pancreatic cancer. Cancer Chemother Pharmacol 2012;70:875-81. [PMID: 23053263 DOI: 10.1007/s00280-012-1979-7] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 1.5] [Reference Citation Analysis]
22 Halfdanarson TR, Haraldsdottir S, Borad MJ. Advances in systemic therapy for advanced pancreatobiliary malignancies. F1000Res 2013;2:105. [PMID: 24327864 DOI: 10.12688/f1000research.2-105.v1] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
23 Heinemann V, Vehling-Kaiser U, Waldschmidt D, Kettner E, Märten A, Winkelmann C, Klein S, Kojouharoff G, Gauler TC, von Weikersthal LF, Clemens MR, Geissler M, Greten TF, Hegewisch-Becker S, Rubanov O, Baake G, Höhler T, Ko YD, Jung A, Neugebauer S, Boeck S. Gemcitabine plus erlotinib followed by capecitabine versus capecitabine plus erlotinib followed by gemcitabine in advanced pancreatic cancer: final results of a randomised phase 3 trial of the 'Arbeitsgemeinschaft Internistische Onkologie' (AIO-PK0104). Gut 2013;62:751-9. [PMID: 22773551 DOI: 10.1136/gutjnl-2012-302759] [Cited by in Crossref: 71] [Cited by in F6Publishing: 66] [Article Influence: 7.1] [Reference Citation Analysis]
24 Pelzer U, Hilbig A, Stieler JM, Bahra M, Sinn M, Gebauer B, Dörken B, Riess H. Intensified chemotherapy and simultaneous treatment with heparin in outpatients with pancreatic cancer - the CONKO 004 pilot trial. BMC Cancer 2014;14:204. [PMID: 24641937 DOI: 10.1186/1471-2407-14-204] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
25 Vaccaro V, Bria E, Sperduti I, Gelibter A, Moscetti L, Mansueto G, Ruggeri EM, Gamucci T, Cognetti F, Milella M. First-line erlotinib and fixed dose-rate gemcitabine for advanced pancreatic cancer. World J Gastroenterol 2013; 19(28): 4511-4519 [PMID: 23901226 DOI: 10.3748/wjg.v19.i28.4511] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
26 Zhu CP, Shi J, Chen YX, Xie WF, Lin Y. Gemcitabine in the chemoradiotherapy for locally advanced pancreatic cancer: a meta-analysis. Radiother Oncol. 2011;99:108-113. [PMID: 21571383 DOI: 10.1016/j.radonc.2011.04.001] [Cited by in Crossref: 55] [Cited by in F6Publishing: 51] [Article Influence: 5.0] [Reference Citation Analysis]
27 Neuzillet C, Tijeras-Raballand A, Bourget P, Cros J, Couvelard A, Sauvanet A, Vullierme MP, Tournigand C, Hammel P. State of the art and future directions of pancreatic ductal adenocarcinoma therapy. Pharmacol Ther. 2015;155:80-104. [PMID: 26299994 DOI: 10.1016/j.pharmthera.2015.08.006] [Cited by in Crossref: 58] [Cited by in F6Publishing: 57] [Article Influence: 8.3] [Reference Citation Analysis]
28 Li D, Xie K, Wolff R, Abbruzzese JL. Pancreatic cancer. The Lancet 2004;363:1049-57. [DOI: 10.1016/s0140-6736(04)15841-8] [Cited by in Crossref: 1360] [Cited by in F6Publishing: 672] [Article Influence: 75.6] [Reference Citation Analysis]
29 Heby M, Elebro J, Nodin B, Jirström K, Eberhard J. Prognostic and predictive significance of podocalyxin-like protein expression in pancreatic and periampullary adenocarcinoma. BMC Clin Pathol 2015;15:10. [PMID: 26028992 DOI: 10.1186/s12907-015-0009-1] [Cited by in Crossref: 29] [Cited by in F6Publishing: 30] [Article Influence: 4.1] [Reference Citation Analysis]
30 Van Cutsem E, Hidalgo M, Canon J, Macarulla T, Bazin I, Poddubskaya E, Manojlovic N, Radenkovic D, Verslype C, Raymond E, Cubillo A, Schueler A, Zhao C, Hammel P. Phase I/II trial of pimasertib plus gemcitabine in patients with metastatic pancreatic cancer. Int J Cancer 2018;143:2053-64. [DOI: 10.1002/ijc.31603] [Cited by in Crossref: 36] [Cited by in F6Publishing: 35] [Article Influence: 9.0] [Reference Citation Analysis]
31 Shen CM, Niu GC, Cui W, Li Q. Improvement of surgical and survival outcomes of patients with pancreatic cancer who underwent pancreaticoduodenectomy: a Chinese experience. Pancreatology 2012;12:206-10. [PMID: 22687374 DOI: 10.1016/j.pan.2012.04.002] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
32 Hirata T, Teshima T, Nishiyama K, Ogawa K, Otani K, Kawaguchi Y, Konishi K, Tomita Y, Takahashi H, Ohigashi H, Ishikawa O. Histopathological effects of preoperative chemoradiotherapy for pancreatic cancer: an analysis for the impact of radiation and gemcitabine doses. Radiother Oncol 2015;114:122-7. [PMID: 25614389 DOI: 10.1016/j.radonc.2015.01.004] [Cited by in Crossref: 24] [Cited by in F6Publishing: 18] [Article Influence: 3.4] [Reference Citation Analysis]
33 Ter Veer E, van Oijen MGH, van Laarhoven HWM. The Use of (Network) Meta-Analysis in Clinical Oncology. Front Oncol 2019;9:822. [PMID: 31508373 DOI: 10.3389/fonc.2019.00822] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 5.7] [Reference Citation Analysis]
34 Xue P, Hang J, Huang W, Li S, Li N, Kodama Y, Matsumoto S, Takaori K, Zhu L, Kanai M. Validation of Lymphocyte-to-Monocyte Ratio as a Prognostic Factor in Advanced Pancreatic Cancer: An East Asian Cohort Study of 2 Countries. Pancreas 2017;46:1011-7. [PMID: 28787331 DOI: 10.1097/MPA.0000000000000891] [Cited by in Crossref: 15] [Cited by in F6Publishing: 9] [Article Influence: 3.8] [Reference Citation Analysis]
35 Lee J, Kim D, Kim JH. Combined administration of naringenin and hesperetin with optimal ratio maximizes the anti-cancer effect in human pancreatic cancer via down regulation of FAK and p38 signaling pathway. Phytomedicine 2019;58:152762. [DOI: 10.1016/j.phymed.2018.11.022] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 6.0] [Reference Citation Analysis]
36 Varadhachary GR, Wolff RA. Current and Evolving Therapies for Metastatic Pancreatic Cancer: Are We Stuck With Cytotoxic Chemotherapy? J Oncol Pract 2016;12:797-805. [PMID: 27621332 DOI: 10.1200/JOP.2016.015586] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.4] [Reference Citation Analysis]
37 Ghosn M, Kourie HR, El Rassy E, Haddad FG, Hanna C, El Karak F, Nasr D. Where does chemotherapy stands in the treatment of ampullary carcinoma? A review of literature. World J Gastrointest Oncol 2016; 8(10): 745-750 [PMID: 27795814 DOI: 10.4251/wjgo.v8.i10.745] [Cited by in CrossRef: 13] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
38 Olszewski AJ, Grossbard ML, Chung MS, Chalasani SB, Malamud S, Mirzoyev T, Kozuch PS. Phase I study of oxaliplatin in combination with gemcitabine, irinotecan, and 5-fluorouracil/leucovorin (G-FLIE) in patients with metastatic solid tumors including adenocarcinoma of the pancreas. J Gastrointest Cancer 2013;44:182-9. [PMID: 23208490 DOI: 10.1007/s12029-012-9466-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
39 Tam VC, Ko YJ, Mittmann N, Cheung MC, Kumar K, Hassan S, Chan KK. Cost-effectiveness of systemic therapies for metastatic pancreatic cancer. Curr Oncol. 2013;20:e90-e106. [PMID: 23559890 DOI: 10.3747/co.20.1223] [Cited by in Crossref: 28] [Cited by in F6Publishing: 37] [Article Influence: 3.1] [Reference Citation Analysis]
40 Mohammad AA. Advanced pancreatic cancer: The standard of care and new opportunities. Oncol Rev 2018;12:370. [PMID: 30344961 DOI: 10.4081/oncol.2018.370] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
41 Xie DR, Yang Q, Chen DL, Jiang ZM, Bi ZF, Ma W, Zhang YD. Gemcitabine-based cytotoxic doublets chemotherapy for advanced pancreatic cancer: updated subgroup meta-analyses of overall survival. Jpn J Clin Oncol. 2010;40:432-441. [PMID: 20147334 DOI: 10.1093/jjco/hyp198] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 2.2] [Reference Citation Analysis]
42 Toesca DAS, Ahmed F, Kashyap M, Baclay JRM, von Eyben R, Pollom EL, Koong AC, Chang DT. Intensified systemic therapy and stereotactic ablative radiotherapy dose for patients with unresectable pancreatic adenocarcinoma. Radiother Oncol 2020;152:63-9. [PMID: 32763253 DOI: 10.1016/j.radonc.2020.07.053] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 2.5] [Reference Citation Analysis]
43 Van Loon K, Espinoza AM, Fogelman DR, Wolff RA, Javle MM, Iyer RV, Picozzi VJ, Martin LK, Bekaii-Saab T, Tempero MA, Foster NR, Kim GP, Ko AH. Should combination chemotherapy serve as the backbone in clinical trials of advanced pancreatic cancer? A pooled analysis of phase II trials of gemcitabine-containing doublets plus bevacizumab. Pancreas 2014;43:343-9. [PMID: 24622062 DOI: 10.1097/MPA.0000000000000095] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 0.9] [Reference Citation Analysis]
44 Kulke MH, Tempero MA, Niedzwiecki D, Hollis DR, Kindler HL, Cusnir M, Enzinger PC, Gorsch SM, Goldberg RM, Mayer RJ. Randomized phase II study of gemcitabine administered at a fixed dose rate or in combination with cisplatin, docetaxel, or irinotecan in patients with metastatic pancreatic cancer: CALGB 89904. J Clin Oncol. 2009;27:5506-5512. [PMID: 19858396 DOI: 10.1200/jco.2009.22.1309] [Cited by in Crossref: 58] [Cited by in F6Publishing: 32] [Article Influence: 4.5] [Reference Citation Analysis]
45 Lee J, Lee J, Kim M, Kim JH. Dietary approach to attenuate human pancreatic cancer growth and migration with innoxiousness. Journal of Functional Foods 2017;30:303-12. [DOI: 10.1016/j.jff.2016.12.032] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.4] [Reference Citation Analysis]
46 Vincent A, Herman J, Schulick R, Hruban RH, Goggins M. Pancreatic cancer. Lancet. 2011;378:607-620. [PMID: 21620466 DOI: 10.1016/s0140-6736(10)62307-0] [Cited by in Crossref: 1377] [Cited by in F6Publishing: 849] [Article Influence: 125.2] [Reference Citation Analysis]
47 Petrelli F, Coinu A, Borgonovo K, Cabiddu M, Ghilardi M, Barni S. Polychemotherapy or gemcitabine in advanced pancreatic cancer: A meta-analysis. Digestive and Liver Disease 2014;46:452-9. [DOI: 10.1016/j.dld.2014.01.001] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.5] [Reference Citation Analysis]
48 Chan SL, Chan ST, Chan EH, He ZX. Systemic treatment for inoperable pancreatic adenocarcinoma: review and update. Chin J Cancer 2014;33:267-76. [PMID: 24472302 DOI: 10.5732/cjc.013.10134] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
49 Moon SY, Joo KR, So YR, Lim JU, Cha JM, Shin HP, Yang YJ. Predictive value of maximum standardized uptake value (SUVmax) on 18F-FDG PET/CT in patients with locally advanced or metastatic pancreatic cancer. Clin Nucl Med. 2013;38:778-783. [PMID: 24107806 DOI: 10.1097/rlu.0b013e31829f8c90] [Cited by in Crossref: 29] [Cited by in F6Publishing: 15] [Article Influence: 3.6] [Reference Citation Analysis]
50 Hartwig W, Büchler MW. Pancreatic Cancer: Current Options for Diagnosis, Staging and Therapeutic Management. Gastrointest Tumors 2013;1:41-52. [PMID: 26673950 DOI: 10.1159/000354992] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
51 Wittwer C, Boeck S, Heinemann V, Haas M, Stieber P, Nagel D, Holdenrieder S. Circulating nucleosomes and immunogenic cell death markers HMGB1, sRAGE and DNAse in patients with advanced pancreatic cancer undergoing chemotherapy. Int J Cancer. 2013;133:2619-2630. [PMID: 23729200 DOI: 10.1002/ijc.28294] [Cited by in Crossref: 20] [Cited by in F6Publishing: 34] [Article Influence: 2.2] [Reference Citation Analysis]
52 Banstola A, Pham TT, Jeong JH, Yook S. Polydopamine-tailored paclitaxel-loaded polymeric microspheres with adhered NIR-controllable gold nanoparticles for chemo-phototherapy of pancreatic cancer. Drug Deliv. 2019;26:629-640. [PMID: 31237149 DOI: 10.1080/10717544.2019.1628118] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 7.0] [Reference Citation Analysis]
53 Schultheis B, Strumberg D, Bergmann L, Graeven U, Hanauske AR, Lipp R, Schuette J, Saito K, Scigalla P, Scheulen ME. Results of a phase II trial of S-1 as first-line treatment of metastatic pancreatic cancer (CESAR-study group). Invest New Drugs. 2012;30:1184-1192. [PMID: 21484249 DOI: 10.1007/s10637-011-9665-x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
54 Mian OY, Ram AN, Tuli R, Herman JM. Management options in locally advanced pancreatic cancer. Curr Oncol Rep 2014;16:388. [PMID: 24740136 DOI: 10.1007/s11912-014-0388-y] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 2.8] [Reference Citation Analysis]
55 Martínez-Bosch N, Iglesias M, Munné-Collado J, Martínez-Cáceres C, Moreno M, Guerra C, Yélamos J, Navarro P. Parp-1 genetic ablation in Ela-myc mice unveils novel roles for Parp-1 in pancreatic cancer. J Pathol 2014;234:214-27. [PMID: 24889936 DOI: 10.1002/path.4384] [Cited by in Crossref: 5] [Cited by in F6Publishing: 11] [Article Influence: 0.6] [Reference Citation Analysis]
56 Páez D, Labonte MJ, Lenz HJ. Pancreatic cancer: medical management (novel chemotherapeutics). Gastroenterol Clin North Am. 2012;41:189-209. [PMID: 22341258 DOI: 10.1016/j.gtc.2011.12.004] [Cited by in Crossref: 26] [Cited by in F6Publishing: 22] [Article Influence: 2.6] [Reference Citation Analysis]
57 Stathis A, Moore MJ. Advanced pancreatic carcinoma: current treatment and future challenges. Nat Rev Clin Oncol 2010;7:163-72. [DOI: 10.1038/nrclinonc.2009.236] [Cited by in Crossref: 516] [Cited by in F6Publishing: 504] [Article Influence: 43.0] [Reference Citation Analysis]
58 Lee JM, Kim H, Kang JS, Byun Y, Choi YJ, Sohn HJ, Han Y, Kwon W, Jang JY. Comparison of perioperative short-term outcomes and oncologic long-term outcomes between open and laparoscopic distal pancreatectomy in patients with pancreatic ductal adenocarcinoma. Ann Surg Treat Res 2021;100:320-8. [PMID: 34136428 DOI: 10.4174/astr.2021.100.6.320] [Reference Citation Analysis]
59 Kanji ZS, Gallinger S. Diagnosis and management of pancreatic cancer. CMAJ. 2013;185:1219-1226. [PMID: 23610017 DOI: 10.1503/cmaj.121368] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 2.6] [Reference Citation Analysis]
60 Kieler M, Unseld M, Bianconi D, Schindl M, Kornek GV, Scheithauer W, Prager GW. Impact of New Chemotherapy Regimens on the Treatment Landscape and Survival of Locally Advanced and Metastatic Pancreatic Cancer Patients. J Clin Med. 2020;9. [PMID: 32121198 DOI: 10.3390/jcm9030648] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 5.0] [Reference Citation Analysis]
61 Ying JE, Zhu LM, Liu BX. Developments in metastatic pancreatic cancer: Is gemcitabine still the standard? World J Gastroenterol 2012; 18(8): 736-745 [PMID: 22371633 DOI: 10.3748/wjg.v18.i8.736] [Cited by in CrossRef: 45] [Cited by in F6Publishing: 41] [Article Influence: 4.5] [Reference Citation Analysis]
62 Li J, Merl M, Lee MX, Kaley K, Saif MW. Safety and efficacy of single-day GemOx regimen in patients with pancreatobiliary cancer: a single institution experience. Expert Opin Drug Saf. 2010;9:207-213. [PMID: 20095915 DOI: 10.1517/14740330903555181] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 0.7] [Reference Citation Analysis]
63 Guo JC, Yang SH. Sequential gemcitabine and platinum versus first-line combination of gemcitabine and platinum for advanced pancreatic cancer treatment: a retrospective study. Int J Clin Oncol 2014;19:634-42. [PMID: 24077663 DOI: 10.1007/s10147-013-0622-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
64 Li JL, Cai Y, Zhang SW, Xiao SW, Li XF, Duan YJ, Li YH, Xu B, Yan K. Combination of Recombinant Adenovirus-p53 with Radiochemotherapy in Unresectable Pancreatic Carcinoma. Chin J Cancer Res 2011;23:194-200. [PMID: 23467436 DOI: 10.1007/s11670-011-0194-0] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
65 Fisher SB, Patel SH, Bagci P, Kooby DA, El-Rayes BF, Staley CA, Adsay NV, Maithel SK. An analysis of human equilibrative nucleoside transporter-1, ribonucleoside reductase subunit M1, ribonucleoside reductase subunit M2, and excision repair cross-complementing gene-1 expression in patients with resected pancreas adenocarcinoma: implications for adjuvant treatment. Cancer. 2013;119:445-453. [PMID: 22569992 DOI: 10.1002/cncr.27619] [Cited by in Crossref: 33] [Cited by in F6Publishing: 26] [Article Influence: 3.3] [Reference Citation Analysis]
66 Trouilloud I, Dubreuil O, Boussaha T, Lepère C, Landi B, Zaanan A, Bachet JB, Taieb J. Medical treatment of pancreatic cancer: new hopes after 10 years of gemcitabine. Clin Res Hepatol Gastroenterol 2011;35:364-74. [PMID: 21435966 DOI: 10.1016/j.clinre.2011.02.002] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.1] [Reference Citation Analysis]
67 Fogelman D, Jafari M, Varadhachary GR, Xiong H, Bullock S, Ozer H, Lin E, Morris J, Cunningham P, Bennett B, Abbruzzese JL, Wolff RA. Bevacizumab plus gemcitabine and oxaliplatin as first-line therapy for metastatic or locally advanced pancreatic cancer: a phase II trial. Cancer Chemother Pharmacol 2011;68:1431-8. [PMID: 21479635 DOI: 10.1007/s00280-011-1601-4] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 1.5] [Reference Citation Analysis]
68 Hoge CW, Sethabutr O, Bodhidatta L, Echeverria P, Robertson DC, Morris JG Jr. Use of a synthetic oligonucleotide probe to detect strains of non-serovar O1 Vibrio cholerae carrying the gene for heat-stable enterotoxin (NAG-ST). J Clin Microbiol. 1990;28:1473-1476. [PMID: 2380369 DOI: 10.1093/carcin/bgt227] [Cited by in Crossref: 74] [Cited by in F6Publishing: 73] [Article Influence: 2.3] [Reference Citation Analysis]
69 Benavides M, Abad A, Ales I, Carrato A, Díaz Rubio E, Gallego J, García-foncillas J, Grávalos C, Laquente B, Pericay C, Rivera F, Tabernero J, Aranda E. TTD consensus document on the diagnosis and management of exocrine pancreatic cancer. Clin Transl Oncol 2014;16:865-78. [DOI: 10.1007/s12094-014-1177-7] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
70 Valsecchi ME, Díaz-Cantón E, de la Vega M, Littman SJ. Recent treatment advances and novel therapies in pancreas cancer: a review. J Gastrointest Cancer 2014;45:190-201. [PMID: 24343588 DOI: 10.1007/s12029-013-9561-z] [Cited by in Crossref: 6] [Cited by in F6Publishing: 15] [Article Influence: 0.9] [Reference Citation Analysis]
71 Moretto R, Raimondo L, De Stefano A, Cella CA, Matano E, De Placido S, Carlomagno C. FOLFIRI in patients with locally advanced or metastatic pancreatic or biliary tract carcinoma: a monoinstitutional experience. Anticancer Drugs. 2013;24:980-985. [PMID: 23928570 DOI: 10.1097/cad.0b013e328364e66b] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
72 Valetti S, Maione F, Mura S, Stella B, Desmaële D, Noiray M, Vergnaud J, Vauthier C, Cattel L, Giraudo E, Couvreur P. Peptide-functionalized nanoparticles for selective targeting of pancreatic tumor. J Control Release 2014;192:29-39. [PMID: 24984010 DOI: 10.1016/j.jconrel.2014.06.039] [Cited by in Crossref: 31] [Cited by in F6Publishing: 30] [Article Influence: 3.9] [Reference Citation Analysis]
73 Sirohi B, Singh A, Dawood S, Shrikhande SV. Advances in chemotherapy for pancreatic cancer. Indian J Surg Oncol 2015;6:47-56. [PMID: 25937764 DOI: 10.1007/s13193-014-0371-y] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
74 Strauss J, Alewine C, Figg WD, Duffy A. Targeting the microenvironment of pancreatic cancer: overcoming treatment barriers and improving local immune responses. Clin Transl Oncol 2016;18:653-9. [PMID: 26661112 DOI: 10.1007/s12094-015-1459-8] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
75 Xenidis N, Chelis L, Amarantidis K, Chamalidou E, Dimopoulos P, Courcoutsakis N, Tentes A, Chiotis A, Prassopoulos P, Kakolyris S. Docetaxel plus gemcitabine in combination with capecitabine as treatment for inoperable pancreatic cancer: a phase II study. Cancer Chemother Pharmacol. 2012;69:477-484. [PMID: 21858532 DOI: 10.1007/s00280-011-1717-6] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.1] [Reference Citation Analysis]
76 Wang Y, Kuramitsu Y, Tokuda K, Baron B, Kitagawa T, Akada J, Maehara S, Maehara Y, Nakamura K. Gemcitabine induces poly (ADP-ribose) polymerase-1 (PARP-1) degradation through autophagy in pancreatic cancer. PLoS One 2014;9:e109076. [PMID: 25271986 DOI: 10.1371/journal.pone.0109076] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 1.5] [Reference Citation Analysis]
77 Li F, Zhao X, Wang H, Zhao R, Ji T, Ren H, Anderson GJ, Nie G, Hao J. Multiple Layer-by-Layer Lipid-Polymer Hybrid Nanoparticles for Improved FOLFIRINOX Chemotherapy in Pancreatic Tumor Models. Adv Funct Mater 2015;25:788-98. [DOI: 10.1002/adfm.201401583] [Cited by in Crossref: 78] [Cited by in F6Publishing: 58] [Article Influence: 9.8] [Reference Citation Analysis]
78 Rossi ML, Rehman AA, Gondi CS. Therapeutic options for the management of pancreatic cancer. World J Gastroenterol 2014; 20(32): 11142-11159 [PMID: 25170201 DOI: 10.3748/wjg.v20.i32.11142] [Cited by in CrossRef: 75] [Cited by in F6Publishing: 68] [Article Influence: 9.4] [Reference Citation Analysis]
79 Postlewait LM, Ethun CG, Kooby DA, Sarmiento JM, Chen Z, Staley CA 3rd, Brutcher E, Adsay V, El-Rayes B, Maithel SK. Combination gemcitabine/cisplatin therapy and ERCC1 expression for resected pancreatic adenocarcinoma: Results of a Phase II prospective trial. J Surg Oncol 2016;114:336-41. [PMID: 27501338 DOI: 10.1002/jso.24317] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
80 Zhang XW, Ma YX, Sun Y, Cao YB, Li Q, Xu CA. Gemcitabine in Combination with a Second Cytotoxic Agent in the First-Line Treatment of Locally Advanced or Metastatic Pancreatic Cancer: a Systematic Review and Meta-Analysis. Target Oncol 2017;12:309-21. [PMID: 28353074 DOI: 10.1007/s11523-017-0486-5] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 5.0] [Reference Citation Analysis]
81 Huang PW, Chang CF, Hung CY, Hsueh SW, Chang PH, Yeh KY, Chen JS, Chen YY, Lu CH, Hung YS, Chou WC. Validation and application of a prognostic model for patients with advanced pancreatic cancer receiving palliative chemotherapy. Cancer Med 2019;8:5554-63. [PMID: 31385456 DOI: 10.1002/cam4.2483] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
82 Cheema AR, O’reilly EM. Management of Metastatic Pancreatic Adenocarcinoma. Surgical Clinics of North America 2016;96:1391-414. [DOI: 10.1016/j.suc.2016.07.011] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
83 Tempero MA, Arnoletti JP, Behrman S, Ben-Josef E, Benson AB 3rd, Berlin JD, Cameron JL, Casper ES, Cohen SJ, Duff M, Ellenhorn JD, Hawkins WG, Hoffman JP, Kuvshinoff BW 2nd, Malafa MP, Muscarella P 2nd, Nakakura EK, Sasson AR, Thayer SP, Tyler DS, Warren RS, Whiting S, Willett C, Wolff RA; NCCN Pancreatic Adenocarcinoma. Pancreatic adenocarcinoma. J Natl Compr Canc Netw 2010;8:972-1017. [PMID: 20876541 DOI: 10.6004/jnccn.2010.0073] [Cited by in Crossref: 122] [Cited by in F6Publishing: 111] [Article Influence: 10.2] [Reference Citation Analysis]
84 O’Reilly EM, Niedzwiecki D, Hall M, Hollis D, Bekaii-Saab T, Pluard T, Douglas K, Abou-Alfa GK, Kindler HL, Schilsky RL. A Cancer and Leukemia Group B phase II study of sunitinib malate in patients with previously treated metastatic pancreatic adenocarcinoma (CALGB 80603). Oncologist. 2010;15:1310-1319. [PMID: 21148613 DOI: 10.1634/theoncologist.2010-0152] [Cited by in Crossref: 46] [Cited by in F6Publishing: 47] [Article Influence: 3.8] [Reference Citation Analysis]
85 Salpeter SR, Malter DS, Luo EJ, Lin AY, Stuart B. Systematic Review of Cancer Presentations with a Median Survival of Six Months or Less. Journal of Palliative Medicine 2012;15:175-85. [DOI: 10.1089/jpm.2011.0192] [Cited by in Crossref: 35] [Cited by in F6Publishing: 28] [Article Influence: 3.5] [Reference Citation Analysis]
86 Iovanna J, Mallmann MC, Gonçalves A, Turrini O, Dagorn JC. Current knowledge on pancreatic cancer. Front Oncol. 2012;2:6. [PMID: 22655256 DOI: 10.3389/fonc.2012.00006] [Cited by in Crossref: 45] [Cited by in F6Publishing: 45] [Article Influence: 4.5] [Reference Citation Analysis]
87 Seufferlein T, Bachet JB, Van Cutsem E, Rougier P;  ESMO Guidelines Working Group. Pancreatic adenocarcinoma: ESMO-ESDO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2012;23 Suppl 7:vii33-vii40. [PMID: 22997452 DOI: 10.1093/annonc/mds224] [Cited by in Crossref: 202] [Cited by in F6Publishing: 201] [Article Influence: 22.4] [Reference Citation Analysis]
88 Kosmidis C, Sapalidis K, Kotidis E, Mixalopoulos N, Zarogoulidis P, Tsavlis D, Baka S, Man YG, Kanellos J. Pancreatic cancer from bench to bedside: molecular pathways and treatment options. Ann Transl Med 2016;4:165. [PMID: 27275478 DOI: 10.21037/atm.2016.05.11] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
89 Lee JM, Lee HS, Hyun JJ, Choi HS, Kim ES, Keum B, Seo YS, Jeen YT, Chun HJ, Um SH, Kim CD. Prognostic value of inflammation-based markers in patients with pancreatic cancer administered gemcitabine and erlotinib. World J Gastrointest Oncol 2016; 8(7): 555-562 [PMID: 27559435 DOI: 10.4251/wjgo.v8.i7.555] [Cited by in CrossRef: 26] [Cited by in F6Publishing: 28] [Article Influence: 4.3] [Reference Citation Analysis]
90 Imamura T, Komatsu S, Ichikawa D, Miyamae M, Okajima W, Ohashi T, Kiuchi J, Nishibeppu K, Konishi H, Shiozaki A. Depleted tumor suppressor miR-107 in plasma relates to tumor progression and is a novel therapeutic target in pancreatic cancer. Sci Rep. 2017;7:5708. [PMID: 28720759 DOI: 10.1038/s41598-017-06137-8] [Cited by in Crossref: 30] [Cited by in F6Publishing: 34] [Article Influence: 6.0] [Reference Citation Analysis]
91 Heinemann V, Reni M, Ychou M, Richel DJ, Macarulla T, Ducreux M. Tumour-stroma interactions in pancreatic ductal adenocarcinoma: rationale and current evidence for new therapeutic strategies. Cancer Treat Rev. 2014;40:118-128. [PMID: 23849556 DOI: 10.1016/j.ctrv.2013.04.004] [Cited by in Crossref: 79] [Cited by in F6Publishing: 84] [Article Influence: 8.8] [Reference Citation Analysis]
92 Springfeld C, Jäger D, Büchler MW, Strobel O, Hackert T, Palmer DH, Neoptolemos JP. Chemotherapy for pancreatic cancer. Presse Med 2019;48:e159-74. [PMID: 30879894 DOI: 10.1016/j.lpm.2019.02.025] [Cited by in Crossref: 42] [Cited by in F6Publishing: 34] [Article Influence: 14.0] [Reference Citation Analysis]
93 Chen JB, Li JL, He LH, Liu WQ, Yao F, Zeng JY, Zhang Y, Xu KQ, Niu LZ, Zuo JS, Xu KC. Radical treatment of stage IV pancreatic cancer by the combination of cryosurgery and iodine-125 seed implantation. World J Gastroenterol 2012; 18(47): 7056-7062 [PMID: 23323008 DOI: 10.3748/wjg.v18.i47.7056] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 12] [Article Influence: 1.4] [Reference Citation Analysis]
94 Gómez-martín C, Hidalgo M, Tabernero J, Isla D. SEOM clinical guidelines for the treatment of pancreatic cancer. Clin Transl Oncol 2011;13:528-35. [DOI: 10.1007/s12094-011-0693-y] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
95 Masu T, Atsukawa M, Nakatsuka K, Shimizu M, Miura D, Arai T, Harimoto H, Kondo C, Kaneko K, Futagami S, Kawamoto C, Takahashi H, Iwakiri K. Anti-CD137 monoclonal antibody enhances trastuzumab-induced, natural killer cell-mediated cytotoxicity against pancreatic cancer cell lines with low human epidermal growth factor-like receptor 2 expression. PLoS One 2018;13:e0200664. [PMID: 30596643 DOI: 10.1371/journal.pone.0200664] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
96 Garrido-Laguna I, Hidalgo M. Pancreatic cancer: from state-of-the-art treatments to promising novel therapies. Nat Rev Clin Oncol. 2015;12:319-334. [PMID: 25824606 DOI: 10.1038/nrclinonc.2015.53] [Cited by in Crossref: 350] [Cited by in F6Publishing: 325] [Article Influence: 50.0] [Reference Citation Analysis]
97 Hwang IG, Jang JS, Oh SY, Lee S, Kwon HC, Lee GW, Go S, Kang MH, Cha YJ, Kang JH. A phase II trial of Erlotinib in combination with gemcitabine and cisplatin in advanced pancreatic cancer. Invest New Drugs 2012;30:2371-6. [PMID: 22302349 DOI: 10.1007/s10637-012-9792-z] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
98 Neuzillet C, Gaujoux S, Williet N, Bachet JB, Bauguion L, Colson Durand L, Conroy T, Dahan L, Gilabert M, Huguet F, Marthey L, Meilleroux J, de Mestier L, Napoléon B, Portales F, Sa Cunha A, Schwarz L, Taieb J, Chibaudel B, Bouché O, Hammel P; Thésaurus National de Cancérologie Digestive (TNCD)., Société Nationale Française de Gastroentérologie (SNFGE)., Fédération Francophone de Cancérologie Digestive (FFCD)., Groupe Coopérateur multidisciplinaire en Oncologie (GERCOR)., Fédération Nationale des Centres de Lutte Contre le Cancer (UNICANCER)., Société Française de Chirurgie Digestive (SFCD)., Société Française d’Endoscopie Digestive (SFED)., Société Française de Radiothérapie Oncologique (SFRO)., Association de Chirurgie Hépato-Bilio-Pancréatique et Transplantation (ACHBT)., Association Française de Chirurgie (AFC). Pancreatic cancer: French clinical practice guidelines for diagnosis, treatment and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, ACHBT, AFC). Dig Liver Dis 2018;50:1257-71. [PMID: 30219670 DOI: 10.1016/j.dld.2018.08.008] [Cited by in Crossref: 53] [Cited by in F6Publishing: 46] [Article Influence: 13.3] [Reference Citation Analysis]
99 Attard CL, Brown S, Alloul K, Moore MJ. Cost-effectiveness of folfirinox for first-line treatment of metastatic pancreatic cancer. Curr Oncol. 2014;21:e41-e51. [PMID: 24523620 DOI: 10.3747/co.21.1327] [Cited by in Crossref: 32] [Cited by in F6Publishing: 34] [Article Influence: 4.0] [Reference Citation Analysis]
100 Deplanque G, Demarchi M, Hebbar M, Flynn P, Melichar B, Atkins J, Nowara E, Moyé L, Piquemal D, Ritter D. A randomized, placebo-controlled phase III trial of masitinib plus gemcitabine in the treatment of advanced pancreatic cancer. Ann Oncol. 2015;26:1194-1200. [PMID: 25858497 DOI: 10.1093/annonc/mdv133] [Cited by in Crossref: 49] [Cited by in F6Publishing: 47] [Article Influence: 7.0] [Reference Citation Analysis]
101 Colucci G, Labianca R, Di Costanzo F, Gebbia V, Cartenì G, Massidda B, Dapretto E, Manzione L, Piazza E, Sannicolò M. Randomized phase III trial of gemcitabine plus cisplatin compared with single-agent gemcitabine as first-line treatment of patients with advanced pancreatic cancer: the GIP-1 study. J Clin Oncol. 2010;28:1645-1651. [PMID: 20194854 DOI: 10.1200/jco.2009.25.4433] [Cited by in Crossref: 201] [Cited by in F6Publishing: 107] [Article Influence: 16.8] [Reference Citation Analysis]
102 Komatsu S, Ichikawa D, Miyamae M, Kawaguchi T, Morimura R, Hirajima S, Okajima W, Ohashi T, Imamura T, Konishi H, Shiozaki A, Ikoma H, Okamoto K, Taniguchi H, Otsuji E. Malignant potential in pancreatic neoplasm; new insights provided by circulating miR-223 in plasma. Expert Opin Biol Ther. 2015;15:773-785. [PMID: 25819175 DOI: 10.1517/14712598.2015.1029914] [Cited by in Crossref: 31] [Cited by in F6Publishing: 40] [Article Influence: 4.4] [Reference Citation Analysis]
103 Gunturu KS, Yao X, Cong X, Thumar JR, Hochster HS, Stein SM, Lacy J. FOLFIRINOX for locally advanced and metastatic pancreatic cancer: single institution retrospective review of efficacy and toxicity. Med Oncol 2013;30. [DOI: 10.1007/s12032-012-0361-2] [Cited by in Crossref: 89] [Cited by in F6Publishing: 88] [Article Influence: 8.9] [Reference Citation Analysis]
104 Spano JP, Moore MJ, Pithavala YK, Ricart AD, Kim S, Rixe O. Phase I study of axitinib (AG-013736) in combination with gemcitabine in patients with advanced pancreatic cancer. Invest New Drugs 2012;30:1531-9. [PMID: 21670972 DOI: 10.1007/s10637-011-9697-2] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.2] [Reference Citation Analysis]
105 Katz MH, Landry J, Kindler HL. Current controversies in the stage-specific multidisciplinary management of pancreatic cancer. Am Soc Clin Oncol Educ Book. 2014;e157-e164. [PMID: 24857097 DOI: 10.14694/edbook_am.2014.34.e157] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
106 Lin X, Huang M, Xie F, Zhou H, Yang J, Huang Q. Gemcitabine inhibits immune escape of pancreatic cancer by down regulating the soluble ULBP2 protein. Oncotarget 2016;7:70092-9. [PMID: 27602753 DOI: 10.18632/oncotarget.11780] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 4.0] [Reference Citation Analysis]
107 Chen Y, Shao Z, Chen W, Xie H, Wu Z, Qin G, Zhao N. A varying-coefficient cox model for the effect of CA19-9 kinetics on overall survival in patients with advanced pancreatic cancer. Oncotarget 2017;8:29925-34. [PMID: 28404893 DOI: 10.18632/oncotarget.15557] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
108 Shibuki T, Mizuta T, Shimokawa M, Koga F, Ueda Y, Nakazawa J, Komori A, Otsu S, Arima S, Fukahori M, Makiyama A, Taguchi H, Honda T, Mitsugi K, Nio K, Ide Y, Ureshino N, Shirakawa T, Otsuka T. Prognostic nomogram for patients with unresectable pancreatic cancer treated with gemcitabine plus nab-paclitaxel or FOLFIRINOX: A post-hoc analysis of a multicenter retrospective study in Japan (NAPOLEON study). BMC Cancer 2022;22:19. [PMID: 34980029 DOI: 10.1186/s12885-021-09139-y] [Reference Citation Analysis]
109 Akasaka H, Sasaki R, Yoshida K, Takayama I, Yamaguchi T, Yoshida H, Mizushina Y. Monogalactosyl diacylglycerol, a replicative DNA polymerase inhibitor, from spinach enhances the anti-cell proliferation effect of gemcitabine in human pancreatic cancer cells. Biochimica et Biophysica Acta (BBA) - General Subjects 2013;1830:2517-25. [DOI: 10.1016/j.bbagen.2012.11.004] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 1.9] [Reference Citation Analysis]
110 Zhao Y, Su C, Zhai H, Tian Y, Sheng W, Miao J, Yang J. Synergistic antitumor effect of adenovirus-mediated hING4 gene therapy and 125I radiation therapy on pancreatic cancer. Cancer Letters 2012;316:211-8. [DOI: 10.1016/j.canlet.2011.11.003] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 1.4] [Reference Citation Analysis]
111 Pelzer U, Schwaner I, Stieler J, Adler M, Seraphin J, Dörken B, Riess H, Oettle H. Best supportive care (BSC) versus oxaliplatin, folinic acid and 5-fluorouracil (OFF) plus BSC in patients for second-line advanced pancreatic cancer: a phase III-study from the German CONKO-study group. Eur J Cancer. 2011;47:1676-1681. [PMID: 21565490 DOI: 10.1016/j.ejca.2011.04.011] [Cited by in Crossref: 214] [Cited by in F6Publishing: 188] [Article Influence: 19.5] [Reference Citation Analysis]
112 Mehta SP. Palliative chemotherapy for pancreatic malignancies. Surg Clin North Am 2010;90:365-75. [PMID: 20362792 DOI: 10.1016/j.suc.2009.12.005] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
113 Muniraj T, Jamidar PA, Aslanian HR. Pancreatic cancer: a comprehensive review and update. Dis Mon. 2013;59:368-402. [PMID: 24183261 DOI: 10.1016/j.disamonth.2013.08.001] [Cited by in Crossref: 76] [Cited by in F6Publishing: 72] [Article Influence: 8.4] [Reference Citation Analysis]
114 Duffy A, Kummar S. Metastatic pancreatic adenocarcinoma: current standards, future directions. Am J Ther 2010;17:79-85. [PMID: 19636248 DOI: 10.1097/MJT.0b013e31819dc8ed] [Reference Citation Analysis]
115 Worni M, Guller U, White RR, Castleberry AW, Pietrobon R, Cerny T, Gloor B, Koeberle D. Modest improvement in overall survival for patients with metastatic pancreatic cancer: a trend analysis using the surveillance, epidemiology, and end results registry from 1988 to 2008. Pancreas. 2013;42:1157-1163. [PMID: 23867367 DOI: 10.1097/mpa.0b013e318291fbc5] [Cited by in Crossref: 41] [Cited by in F6Publishing: 31] [Article Influence: 5.1] [Reference Citation Analysis]
116 Herreros-Villanueva M, Hijona E, Cosme A, Bujanda L. Adjuvant and neoadjuvant treatment in pancreatic cancer. World J Gastroenterol 2012; 18(14): 1565-1572 [PMID: 22529684 DOI: 10.3748/wjg.v18.i14.1565] [Cited by in CrossRef: 36] [Cited by in F6Publishing: 34] [Article Influence: 3.6] [Reference Citation Analysis]
117 Pelzer U, Sinn M, Stieler J, Riess H. [Multimodal treatment of pancreatic cancer]. Internist (Berl). 2014;55:31-36. [PMID: 24399472 DOI: 10.1007/s00108-013-3316-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
118 Waheed A, Purvey S, Saif MW. Masitinib in treatment of pancreatic cancer. Expert Opin Pharmacother 2018;19:759-64. [PMID: 29638149 DOI: 10.1080/14656566.2018.1459566] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
119 Lee J, Lee J, Sim W, Kim JH. Differential Dependency of Human Pancreatic Cancer Cells on Targeting PTEN via PLK 1 Expression. Cancers (Basel) 2020;12:E277. [PMID: 31979216 DOI: 10.3390/cancers12020277] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
120 Zhou X, Liao X, Wang X, Huang K, Yang C, Yu T, Liu J, Han C, Zhu G, Su H, Qin W, Han Q, Liu Z, Huang J, Gong Y, Ye X, Peng T. Clinical significance and prospective molecular mechanism of C‑C motif chemokine receptors in patients with early‑stage pancreatic ductal adenocarcinoma after pancreaticoduodenectomy. Oncol Rep 2019;42:1856-68. [PMID: 31432181 DOI: 10.3892/or.2019.7277] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
121 Kawaguchi T, Komatsu S, Ichikawa D, Morimura R, Tsujiura M, Konishi H, Takeshita H, Nagata H, Arita T, Hirajima S. Clinical impact of circulating miR-221 in plasma of patients with pancreatic cancer. Br J Cancer. 2013;108:361-369. [PMID: 23329235 DOI: 10.1038/bjc.2012.546] [Cited by in Crossref: 137] [Cited by in F6Publishing: 142] [Article Influence: 15.2] [Reference Citation Analysis]
122 Soo RA, Yong WP, Innocenti F. Systemic therapies for pancreatic cancer--the role of pharmacogenetics. Curr Drug Targets 2012;13:811-28. [PMID: 22458528 DOI: 10.2174/138945012800564068] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.0] [Reference Citation Analysis]
123 Heinrich S, Pestalozzi B, Lesurtel M, Berrevoet F, Laurent S, Delpero JR, Raoul JL, Bachellier P, Dufour P, Moehler M, Weber A, Lang H, Rogiers X, Clavien PA. Adjuvant gemcitabine versus NEOadjuvant gemcitabine/oxaliplatin plus adjuvant gemcitabine in resectable pancreatic cancer: a randomized multicenter phase III study (NEOPAC study). BMC Cancer. 2011;11:346. [PMID: 21831266 DOI: 10.1186/1471-2407-11-346] [Cited by in Crossref: 71] [Cited by in F6Publishing: 65] [Article Influence: 6.5] [Reference Citation Analysis]
124 Tempero MA, Berlin J, Ducreux M, Haller D, Harper P, Khayat D, Schmoll HJ, Sobrero A, Van Cutsem E. Pancreatic cancer treatment and research: an international expert panel discussion. Ann Oncol. 2011;22:1500-1506. [PMID: 21199884 DOI: 10.1093/annonc/mdq545] [Cited by in Crossref: 34] [Cited by in F6Publishing: 33] [Article Influence: 3.1] [Reference Citation Analysis]
125 Hu Q, Jiang JX, Luo L, Yang X, Lin X, Dinglin XX, Zhang W, Wu JY, Yao HR. A systematic review of gemcitabine and taxanes combination therapy randomized trials for metastatic breast cancer. Springerplus 2014;3:293. [PMID: 26034661 DOI: 10.1186/2193-1801-3-293] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
126 Todaka A, Fukutomi A, Boku N, Onozawa Y, Hironaka S, Yasui H, Yamazaki K, Taku K, Machida N, Sakamoto T. S-1 monotherapy as second-line treatment for advanced pancreatic cancer after gemcitabine failure. Jpn J Clin Oncol. 2010;40:567-572. [PMID: 20189975 DOI: 10.1093/jjco/hyq005] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 1.4] [Reference Citation Analysis]
127 Sjoquist KM, Chin VT, Chantrill LA, O’Connor C, Hemmings C, Chang DK, Chou A, Pajic M, Johns AL, Nagrial AM, Biankin AV, Yip D. Personalising pancreas cancer treatment: When tissue is the issue. World J Gastroenterol 2014; 20(24): 7849-7863 [PMID: 24976722 DOI: 10.3748/wjg.v20.i24.7849] [Cited by in CrossRef: 18] [Cited by in F6Publishing: 17] [Article Influence: 2.3] [Reference Citation Analysis]
128 Chao YJ, Sy ED, Hsu HP, Shan YS. Predictors for resectability and survival in locally advanced pancreatic cancer after gemcitabine-based neoadjuvant therapy. BMC Surg 2014;14:72. [PMID: 25258022 DOI: 10.1186/1471-2482-14-72] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 0.9] [Reference Citation Analysis]
129 Lundgren S, Warfvinge CF, Elebro J, Heby M, Nodin B, Krzyzanowska A, Bjartell A, Leandersson K, Eberhard J, Jirström K. The Prognostic Impact of NK/NKT Cell Density in Periampullary Adenocarcinoma Differs by Morphological Type and Adjuvant Treatment. PLoS One 2016;11:e0156497. [PMID: 27275582 DOI: 10.1371/journal.pone.0156497] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 2.3] [Reference Citation Analysis]
130 Adamska A, Domenichini A, Falasca M. Pancreatic Ductal Adenocarcinoma: Current and Evolving Therapies. Int J Mol Sci. 2017;18. [PMID: 28640192 DOI: 10.3390/ijms18071338] [Cited by in Crossref: 210] [Cited by in F6Publishing: 198] [Article Influence: 42.0] [Reference Citation Analysis]
131 Chen B, Xu M, Zhang H, Xu MZ, Wang XJ, Tang QH, Tang JY. The Antipancreatic Cancer Activity of OSI-027, a Potent and Selective Inhibitor of mTORC1 and mTORC2. DNA Cell Biol 2015;34:610-7. [PMID: 26284306 DOI: 10.1089/dna.2015.2886] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.6] [Reference Citation Analysis]
132 Karanikas M, Esempidis A, Chasan ZT, Deftereou T, Antonopoulou M, Bozali F, Amarantidis K, Man YG. Pancreatic Cancer from Molecular Pathways to Treatment Opinion. J Cancer 2016;7:1328-39. [PMID: 27390608 DOI: 10.7150/jca.15419] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 2.2] [Reference Citation Analysis]
133 Glimelius B. Any progress in pancreatic cancer? Well, but progress for Acta Oncologica. Acta Oncol 2010;49:404-6. [PMID: 20397771 DOI: 10.3109/02841861003724837] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
134 Chiu J, Yau T. Metastatic pancreatic cancer: are we making progress in treatment. Gastroenterol Res Pract. 2012;2012:898931. [PMID: 23304129 DOI: 10.1155/2012/898931] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
135 Jang JY, Kang JS, Han Y, Heo JS, Choi SH, Choi DW, Park SJ, Han SS, Yoon DS, Park JS, Yu HC, Kang KJ, Kim SG, Lee H, Kwon W, Yoon YS, Han HS, Kim SW. Long-term outcomes and recurrence patterns of standard versus extended pancreatectomy for pancreatic head cancer: a multicenter prospective randomized controlled study. J Hepatobiliary Pancreat Sci 2017;24:426-33. [PMID: 28514000 DOI: 10.1002/jhbp.465] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 4.0] [Reference Citation Analysis]
136 Conroy T, Mitry E. [Chemotherapy of metastatic pancreatic adenocarcinoma: challenges and encouraging results]. Bull Cancer 2011;98:1439-46. [PMID: 22133915 DOI: 10.1684/bdc.2011.1494] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
137 Rachagani S, Macha MA, Ponnusamy MP, Haridas D, Kaur S, Jain M, Batra SK. MUC4 potentiates invasion and metastasis of pancreatic cancer cells through stabilization of fibroblast growth factor receptor 1. Carcinogenesis. 2012;33:1953-1964. [PMID: 22791819 DOI: 10.1093/carcin/bgs225] [Cited by in Crossref: 57] [Cited by in F6Publishing: 51] [Article Influence: 5.7] [Reference Citation Analysis]
138 Gonçalves A, Gilabert M, François E, Dahan L, Perrier H, Lamy R, Re D, Largillier R, Gasmi M, Tchiknavorian X. BAYPAN study: a double-blind phase III randomized trial comparing gemcitabine plus sorafenib and gemcitabine plus placebo in patients with advanced pancreatic cancer. Ann Oncol. 2012;23:2799-2805. [PMID: 22771827 DOI: 10.1093/annonc/mds135] [Cited by in Crossref: 142] [Cited by in F6Publishing: 131] [Article Influence: 14.2] [Reference Citation Analysis]
139 Long Y, Sun Q, Wu J, Wang Y, Jiao S. Allogeneic cell-based immunotherapy combined with chemotherapy and targeted therapy in advanced pancreatic cancer with metastases: A case report. Oncol Lett 2014;7:1594-8. [PMID: 24765183 DOI: 10.3892/ol.2014.1908] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
140 Zhang Q, Wang H, Ran L, Zhang Z, Jiang R. The preclinical evaluation of TIC10/ONC201 as an anti-pancreatic cancer agent. Biochem Biophys Res Commun 2016;476:260-6. [PMID: 27233611 DOI: 10.1016/j.bbrc.2016.05.106] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 3.5] [Reference Citation Analysis]
141 Lin PJ, Concannon TW, Greenberg D, Cohen JT, Rossi G, Hille J, Auerbach HR, Fang CH, Nadler ES, Neumann PJ. Does framing of cancer survival affect perceived value of care? A willingness-to-pay survey of US residents. Expert Rev Pharmacoecon Outcomes Res 2013;13:513-22. [PMID: 23977977 DOI: 10.1586/14737167.2013.814948] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
142 Francois E, Bennouna J, Chamorey E, Etienne-Grimaldi MC, Renée N, Senellart H, Michel C, Follana P, Mari V, Douillard JY, Milano G. Phase I trial of gemcitabine combined with capecitabine and erlotinib in advanced pancreatic cancer: a clinical and pharmacological study. Chemotherapy 2012;58:371-80. [PMID: 23235319 DOI: 10.1159/000343969] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
143 Campen CJ, Dragovich T, Baker AF. Management strategies in pancreatic cancer. Am J Health Syst Pharm 2011;68:573-84. [PMID: 21411798 DOI: 10.2146/ajhp100254] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 1.8] [Reference Citation Analysis]
144 Shan T, Ma Q, Zhang D, Guo K, Liu H, Wang F, Wu E. β2-adrenoceptor blocker synergizes with gemcitabine to inhibit the proliferation of pancreatic cancer cells via apoptosis induction. Eur J Pharmacol 2011;665:1-7. [PMID: 21570961 DOI: 10.1016/j.ejphar.2011.04.055] [Cited by in Crossref: 32] [Cited by in F6Publishing: 31] [Article Influence: 2.9] [Reference Citation Analysis]
145 Moss RA, Lee C. Current and emerging therapies for the treatment of pancreatic cancer. Onco Targets Ther 2010;3:111-27. [PMID: 20856847 DOI: 10.2147/ott.s7203] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 2.0] [Reference Citation Analysis]
146 Lee KC, Maturo C, Perera CN, Luddy J, Rodriguez R, Shorr R. Translational assessment of mitochondrial dysfunction of pancreatic cancer from in vitro gene microarray and animal efficacy studies, to early clinical studies, via the novel tumor-specific anti-mitochondrial agent, CPI-613. Ann Transl Med 2014;2:91. [PMID: 25405166 DOI: 10.3978/j.issn.2305-5839.2014.05.08] [Cited by in F6Publishing: 8] [Reference Citation Analysis]
147 Abrams RA. Radiotherapy in the adjuvant management of pancreatic adenocarcinoma: is it helpful? Expert Review of Gastroenterology & Hepatology 2014;6:149-61. [DOI: 10.1586/egh.12.3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
148 Zhang DS, Wang DS, Wang ZQ, Wang FH, Luo HY, Qiu MZ, Wang F, Li YH, Xu RH. Phase I/II study of albumin-bound nab-paclitaxel plus gemcitabine administered to Chinese patients with advanced pancreatic cancer. Cancer Chemother Pharmacol. 2013;71:1065-1072. [PMID: 23483298 DOI: 10.1007/s00280-013-2102-4] [Cited by in Crossref: 18] [Cited by in F6Publishing: 23] [Article Influence: 2.0] [Reference Citation Analysis]
149 Seufferlein T, Adler G. [The S3 guideline exocrine pancreatic cancer]. Med Klin (Munich). 2009;104:869-874. [PMID: 19916076 DOI: 10.1007/s00063-009-1183-7] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
150 Desai S, Ben-Josef E, Griffith KA, Simeone D, Greenson JK, Francis IR, Hampton J, Colletti L, Chang AE, Lawrence TS. Gemcitabine-based combination chemotherapy followed by radiation with capecitabine as adjuvant therapy for resected pancreas cancer. Int J Radiat Oncol Biol Phys. 2009;75:1450-1455. [PMID: 19409732 DOI: 10.1016/j.ijrobp.2009.01.023] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
151 Hidalgo M, Cascinu S, Kleeff J, Labianca R, Löhr JM, Neoptolemos J, Real FX, Van Laethem JL, Heinemann V. Addressing the challenges of pancreatic cancer: future directions for improving outcomes. Pancreatology. 2013;15:8-18. [PMID: 25547205 DOI: 10.1016/j.pan.2014.10.001] [Cited by in Crossref: 222] [Cited by in F6Publishing: 222] [Article Influence: 27.8] [Reference Citation Analysis]
152 Kourelis TV, Siegel RD. Metformin and cancer: new applications for an old drug. Med Oncol. 2012;29:1314-1327. [PMID: 21301998 DOI: 10.1007/s12032-011-9846-7] [Cited by in Crossref: 176] [Cited by in F6Publishing: 177] [Article Influence: 16.0] [Reference Citation Analysis]
153 He M, Sun J, Zhao D, He H, Wang B, Xu L, Shang Y, Ren S, Zhang Y, Wu T. Modified-FOLFIRINOX combined with deep regional hyperthermia in pancreatic cancer: a retrospective study in Chinese patients.Int J Hyperthermia. 2019;36:394-402. [PMID: 30917701 DOI: 10.1080/02656736.2019.1579371] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
154 Merchan JR, Ferrell A, Macintyre J, Ciombor KK, Levi J, Ribeiro A, Sleeman D, Flores A, Lopes G, Rocha-lima CM. Phase II Study of Gemcitabine, Oxaliplatin, and Cetuximab in Advanced Pancreatic Cancer. American Journal of Clinical Oncology 2012;35:446-50. [DOI: 10.1097/coc.0b013e31821862fb] [Cited by in Crossref: 12] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
155 Malik NK, May KS, Chandrasekhar R, Wee W, Flaherty L, Iyer R, Gibbs J, Kuvshinoff B, Wilding G, Warren G, Yang GY. Treatment of locally advanced unresectable pancreatic cancer: a 10-year experience. J Gastrointest Oncol 2012;3:326-34. [PMID: 23205309 DOI: 10.3978/j.issn.2078-6891.2012.029] [Cited by in F6Publishing: 28] [Reference Citation Analysis]
156 Yang L, Yang L, Tian W, Li J, Liu J, Zhu M, Zhang Y, Yang Y, Liu F, Zhang Q. Resveratrol plays dual roles in pancreatic cancer cells. J Cancer Res Clin Oncol. 2014;140:749-755. [PMID: 24604347 DOI: 10.1007/s00432-014-1624-4] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 3.1] [Reference Citation Analysis]
157 Xu L, Liu YP. Advances in chemotherapy of advanced pancreatic cancer. Shijie Huaren Xiaohua Zazhi 2010; 18(25): 2685-2689 [DOI: 10.11569/wcjd.v18.i25.2685] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
158 Oh SY, Kim HJ, Kim TH, Lee GW, Kim HG, Jeong CY, Kwon HC, Kang JH. Pilot study of irinotecan/oxalipltin (IROX) combination chemotherapy for patients with gemcitabine- and 5-fluorouracil- refractory pancreatic cancer. Invest New Drugs. 2010;28:343-349. [PMID: 19444385 DOI: 10.1007/s10637-009-9265-1] [Cited by in Crossref: 12] [Cited by in F6Publishing: 15] [Article Influence: 0.9] [Reference Citation Analysis]
159 Kullmann F, Hartmann A, Stöhr R, Messmann H, Dollinger MM, Trojan J, Fuchs M, Hollerbach S, Harder J, Troppmann M. KRAS mutation in metastatic pancreatic ductal adenocarcinoma: results of a multicenter phase II study evaluating efficacy of cetuximab plus gemcitabine/oxaliplatin (GEMOXCET) in first-line therapy. Oncology. 2011;81:3-8. [PMID: 21894049 DOI: 10.1159/000330194] [Cited by in Crossref: 33] [Cited by in F6Publishing: 28] [Article Influence: 3.0] [Reference Citation Analysis]
160 Hu J, Zhao G, Wang HX, Tang L, Xu YC, Ma Y, Zhang FC. A meta-analysis of gemcitabine containing chemotherapy for locally advanced and metastatic pancreatic adenocarcinoma. J Hematol Oncol 2011;4:11. [PMID: 21439076 DOI: 10.1186/1756-8722-4-11] [Cited by in Crossref: 42] [Cited by in F6Publishing: 42] [Article Influence: 3.8] [Reference Citation Analysis]
161 Cao C, Kuang M, Xu W, Zhang X, Chen J, Tang C. Gemcitabine plus S-1: a hopeful frontline treatment for Asian patients with unresectable advanced pancreatic cancer. Jpn J Clin Oncol 2015;45:1122-30. [PMID: 26518328 DOI: 10.1093/jjco/hyv141] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.1] [Reference Citation Analysis]
162 Ryu JK. Recent Advances in Palliative Chemotherapy for Unresectable Pancreatic Cancer. Korean J Gastroenterol 2015;66:150. [DOI: 10.4166/kjg.2015.66.3.150] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
163 Pelzer U, Opitz B, Deutschinoff G, Stauch M, Reitzig PC, Hahnfeld S, Müller L, Grunewald M, Stieler JM, Sinn M, Denecke T, Bischoff S, Oettle H, Dörken B, Riess H. Efficacy of Prophylactic Low–Molecular Weight Heparin for Ambulatory Patients With Advanced Pancreatic Cancer: Outcomes From the CONKO-004 Trial. JCO 2015;33:2028-34. [DOI: 10.1200/jco.2014.55.1481] [Cited by in Crossref: 146] [Cited by in F6Publishing: 71] [Article Influence: 20.9] [Reference Citation Analysis]
164 Katopodis O, Souglakos J, Stathopoulos E, Christopoulou A, Kontopodis E, Kotsakis A, Kalbakis K, Kentepozidis N, Polyzos A, Hatzidaki D, Georgoulias V. Frontline treatment with gemcitabine, oxaliplatin and erlotinib for the treatment of advanced or metastatic pancreatic cancer: a multicenter phase II study of the Hellenic Oncology Research Group (HORG). Cancer Chemother Pharmacol 2014;74:333-40. [PMID: 24930058 DOI: 10.1007/s00280-014-2509-6] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
165 Patel BB, Majumdar AP. Synergistic role of curcumin with current therapeutics in colorectal cancer: minireview. Nutr Cancer 2009;61:842-6. [PMID: 20155625 DOI: 10.1080/01635580903285106] [Cited by in Crossref: 53] [Cited by in F6Publishing: 50] [Article Influence: 4.4] [Reference Citation Analysis]
166 Brunner TB, Sauer R, Fietkau R. Gemcitabine/cisplatin versus 5-fluorouracil/mitomycin C chemoradiotherapy in locally advanced pancreatic cancer: a retrospective analysis of 93 patients. Radiat Oncol 2011;6:88. [PMID: 21794119 DOI: 10.1186/1748-717X-6-88] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
167 Gong J, Tuli R, Shinde A, Hendifar AE. Meta-analyses of treatment standards for pancreatic cancer. Mol Clin Oncol 2016;4:315-25. [PMID: 26998283 DOI: 10.3892/mco.2015.716] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 2.6] [Reference Citation Analysis]
168 Ettrich TJ, Seufferlein T. Systemic Therapy for Metastatic Pancreatic Cancer. Curr Treat Options Oncol 2021;22:106. [PMID: 34665339 DOI: 10.1007/s11864-021-00895-4] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
169 Winther SB, Bjerregaard JK, Schonnemann KR, Ejlsmark MW, Krogh M, Jensen HA, Pfeiffer P. S-1 (Teysuno) and gemcitabine in Caucasian patients with unresectable pancreatic adenocarcinoma. Cancer Chemother Pharmacol 2018;81:573-8. [DOI: 10.1007/s00280-018-3528-5] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
170 Conroy T, Gavoille C, Adenis A. Metastatic pancreatic cancer: old drugs, new paradigms. Curr Opin Oncol. 2011;23:390-395. [PMID: 21505335 DOI: 10.1097/cco.0b013e3283473610] [Cited by in Crossref: 23] [Cited by in F6Publishing: 15] [Article Influence: 2.1] [Reference Citation Analysis]
171 Ciliberto D, Botta C, Correale P, Rossi M, Caraglia M, Tassone P, Tagliaferri P. Role of gemcitabine-based combination therapy in the management of advanced pancreatic cancer: a meta-analysis of randomised trials. Eur J Cancer 2013;49:593-603. [PMID: 22989511 DOI: 10.1016/j.ejca.2012.08.019] [Cited by in Crossref: 76] [Cited by in F6Publishing: 71] [Article Influence: 7.6] [Reference Citation Analysis]
172 Vaccaro V, Sperduti I, Vari S, Bria E, Melisi D, Garufi C, Nuzzo C, Scarpa A, Tortora G, Cognetti F, Reni M, Milella M. Metastatic pancreatic cancer: Is there a light at the end of the tunnel? World J Gastroenterol 2015; 21(16): 4788-4801 [PMID: 25944992 DOI: 10.3748/wjg.v21.i16.4788] [Cited by in CrossRef: 45] [Cited by in F6Publishing: 44] [Article Influence: 6.4] [Reference Citation Analysis]
173 Fuereder T, Stift J, Kuehrer I, Stranzl N, Hoeflmayer D, Kornek G, Scheithauer W. Response to GEMOX plus erlotinib in pancreatic cancer is associated with ERCC1 overexpression. Eur J Clin Invest. 2014;44:958-964. [PMID: 25145842 DOI: 10.1111/eci.12329] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
174 Min Y, Caster JM, Eblan MJ, Wang AZ. Clinical Translation of Nanomedicine. Chem Rev 2015;115:11147-90. [PMID: 26088284 DOI: 10.1021/acs.chemrev.5b00116] [Cited by in Crossref: 424] [Cited by in F6Publishing: 377] [Article Influence: 60.6] [Reference Citation Analysis]
175 Courtin A, Richards FM, Bapiro TE, Bramhall JL, Neesse A, Cook N, Krippendorff BF, Tuveson DA, Jodrell DI. Anti-tumour efficacy of capecitabine in a genetically engineered mouse model of pancreatic cancer. PLoS One 2013;8:e67330. [PMID: 23840665 DOI: 10.1371/journal.pone.0067330] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 2.0] [Reference Citation Analysis]
176 Maithel SK, Coban I, Kneuertz PJ, Kooby DA, El-rayes BF, Kauh JS, Sarmiento J, Staley CA, Volkan Adsay N. Differential Expression of ERCC1 in Pancreas Adenocarcinoma: High Tumor Expression is Associated with Earlier Recurrence and Shortened Survival after Resection. Ann Surg Oncol 2011;18:2699-705. [DOI: 10.1245/s10434-011-1610-x] [Cited by in Crossref: 31] [Cited by in F6Publishing: 28] [Article Influence: 2.8] [Reference Citation Analysis]
177 Gillen S, Schuster T, Meyer Zum Büschenfelde C, Friess H, Kleeff J. Preoperative/neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of response and resection percentages. PLoS Med 2010;7:e1000267. [PMID: 20422030 DOI: 10.1371/journal.pmed.1000267] [Cited by in Crossref: 923] [Cited by in F6Publishing: 846] [Article Influence: 76.9] [Reference Citation Analysis]
178 Bauer C, Dauer M, Saraj S, Schnurr M, Bauernfeind F, Sterzik A, Junkmann J, Jakl V, Kiefl R, Oduncu F. Dendritic cell-based vaccination of patients with advanced pancreatic carcinoma: results of a pilot study. Cancer Immunol Immunother. 2011;60:1097-1107. [PMID: 21547597 DOI: 10.1007/s00262-011-1023-5] [Cited by in Crossref: 35] [Cited by in F6Publishing: 34] [Article Influence: 3.2] [Reference Citation Analysis]
179 Ibrahim AM, Wang YH. Viro-immune therapy: A new strategy for treatment of pancreatic cancer. World J Gastroenterol 2016; 22(2): 748-763 [PMID: 26811622 DOI: 10.3748/wjg.v22.i2.748] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
180 Park JK, Kim Y, Kim H, Jeon J, Kim TW, Park JH, Hwnag YI, Lee WJ, Kang JS. The anti-fibrotic effect of GV1001 combined with gemcitabine on treatment of pancreatic ductal adenocarcinoma. Oncotarget 2016;7:75081-93. [PMID: 27655706 DOI: 10.18632/oncotarget.12057] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
181 Philip PA, Chansky K, LeBlanc M, Rubinstein L, Seymour L, Ivy SP, Alberts SR, Catalano PJ, Crowley J. Historical controls for metastatic pancreatic cancer: benchmarks for planning and analyzing single-arm phase II trials. Clin Cancer Res 2014;20:4176-85. [PMID: 24914040 DOI: 10.1158/1078-0432.CCR-13-2024] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 1.1] [Reference Citation Analysis]
182 Taieb J, Pointet AL, Van Laethem JL, Laquente B, Pernot S, Lordick F, Reni M. What treatment in 2017 for inoperable pancreatic cancers? Ann Oncol. 2017;28:1473-1483. [PMID: 28459988 DOI: 10.1093/annonc/mdx174] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 5.3] [Reference Citation Analysis]
183 Ji T, Li S, Zhang Y, Lang J, Ding Y, Zhao X, Zhao R, Li Y, Shi J, Hao J. An MMP-2 Responsive Liposome Integrating Antifibrosis and Chemotherapeutic Drugs for Enhanced Drug Perfusion and Efficacy in Pancreatic Cancer. ACS Appl Mater Interfaces. 2016;8:3438-3445. [PMID: 26759926 DOI: 10.1021/acsami.5b11619] [Cited by in Crossref: 78] [Cited by in F6Publishing: 82] [Article Influence: 13.0] [Reference Citation Analysis]
184 Zhu X, Cao Y, Lu M, Zhao X, Jiang L, Ye Y, Ju X, Zhang H. Stereotactic body radiation therapy with sequential S-1 for patients with locally advanced pancreatic cancer and poor performance status: An open-label, single-arm, phase 2 trial. Radiother Oncol 2021;162:178-84. [PMID: 34274393 DOI: 10.1016/j.radonc.2021.07.009] [Reference Citation Analysis]
185 Miyamae M, Komatsu S, Ichikawa D, Kawaguchi T, Hirajima S, Okajima W, Ohashi T, Imamura T, Konishi H, Shiozaki A. Plasma microRNA profiles: identification of miR-744 as a novel diagnostic and prognostic biomarker in pancreatic cancer. Br J Cancer. 2015;113:1467-1476. [PMID: 26505678 DOI: 10.1038/bjc.2015.366] [Cited by in Crossref: 54] [Cited by in F6Publishing: 57] [Article Influence: 7.7] [Reference Citation Analysis]
186 Vicente E, Quijano Y, Ielpo B, Duran H, Diaz E, Fabra I, Oliva C, Olivares S, Caruso R, Ferri V, Ceron R, Moreno A. Is arterial infiltration still a criterion for unresectability in pancreatic adenocarcinoma? Cir Esp 2014;92:305-15. [PMID: 24636076 DOI: 10.1016/j.ciresp.2013.11.001] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
187 Lim JY, Cho JH, Lee SJ, Lee DK, Yoon DS, Cho JY. Gemcitabine Combined with Capecitabine Compared to Gemcitabine with or without Erlotinib as First-Line Chemotherapy in Patients with Advanced Pancreatic Cancer. Cancer Res Treat. 2015;47:266-273. [PMID: 25327494 DOI: 10.4143/crt.2013.158] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
188 Pelzer U, Hilbig A, Sinn M, Stieler J, Bahra M, Dörken B, Riess H. Value of carbohydrate antigen 19-9 in predicting response and therapy control in patients with metastatic pancreatic cancer undergoing first-line therapy. Front Oncol 2013;3:155. [PMID: 23785668 DOI: 10.3389/fonc.2013.00155] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 2.2] [Reference Citation Analysis]
189 Ko AH. FOLFIRINOX: A Small Step or a Great Leap Forward? JCO 2011;29:3727-9. [DOI: 10.1200/jco.2011.37.3464] [Cited by in Crossref: 18] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
190 Lin M, Yuan Y, Liu S, Shi J, Long X, Niu L, Chen J, Li Q, Xu K. Prospective study of the safety and efficacy of a pancreatic cancer stem cell vaccine. J Cancer Res Clin Oncol 2015;141:1827-33. [DOI: 10.1007/s00432-015-1968-4] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
191 Salami A, Obaid T, Joshi AR. Trends in the clinical presentation, treatment, and survival for pancreatic adenocarcinoma. The American Journal of Surgery 2019;217:103-7. [DOI: 10.1016/j.amjsurg.2018.05.017] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
192 Heinemann V, Haas M, Boeck S. Systemic treatment of advanced pancreatic cancer. Cancer Treat Rev 2012;38:843-53. [PMID: 22226241 DOI: 10.1016/j.ctrv.2011.12.004] [Cited by in Crossref: 81] [Cited by in F6Publishing: 81] [Article Influence: 8.1] [Reference Citation Analysis]
193 Colloca G. Performance status as prognostic factor in phase III trials of first-line chemotherapy of unresectable or metastatic pancreatic cancer: A trial-level meta-analysis. Asia Pac J Clin Oncol 2021. [PMID: 34161667 DOI: 10.1111/ajco.13598] [Reference Citation Analysis]
194 Bachet JB, Chibaudel B, Bonnetain F, Validire P, Hammel P, André T, Louvet C; GERCOR group. A randomized phase II study of weekly nab-paclitaxel plus gemcitabine or simplified LV5FU2 as first-line therapy in patients with metastatic pancreatic cancer: the AFUGEM GERCOR trial. BMC Cancer 2015;15:653. [PMID: 26445094 DOI: 10.1186/s12885-015-1656-4] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
195 Pentheroudakis G, Greco F, Pavlidis N. Molecular assignment of tissue of origin in cancer of unknown primary may not predict response to therapy or outcome: A systematic literature review. Cancer Treatment Reviews 2009;35:221-7. [DOI: 10.1016/j.ctrv.2008.10.003] [Cited by in Crossref: 67] [Cited by in F6Publishing: 54] [Article Influence: 5.2] [Reference Citation Analysis]
196 Verslype C, Van Cutsem E, Dicato M, Arber N, Berlin J, Büchler M, Cervantes A, Ciardiello F, Ducreux M, Douillard J, Grothey A, Haller D, Haustermans K, Heinemann V, Hidalgo M, Labianca R, Li J, Marshall J, Nordlinger B, O'reilly E, Roth A, Rougier P, Ryan D, Schmiegel W, Seufferlein T, Schmoll H, Sobrero A, Tabernero J, Tempero M, Van Laethem J, Ychou M, Zalcberg J. The management of metastatic pancreatic cancer: expert discussion and recommendations from the 14th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2012. Annals of Oncology 2013;24:iv5-iv10. [DOI: 10.1093/annonc/mdt200] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
197 Arslan C, Yalcin S. Current and future systemic treatment options in metastatic pancreatic cancer. J Gastrointest Oncol. 2014;5:280-295. [PMID: 25083302 DOI: 10.3978/j.issn.2078-6891.2014.030] [Cited by in F6Publishing: 17] [Reference Citation Analysis]
198 Kita A, Fujiya M, Konishi H, Tanaka H, Kashima S, Iwama T, Ijiri M, Murakami Y, Takauji S, Goto T, Sakatani A, Ando K, Ueno N, Ogawa N, Okumura T. Probiotic‑derived ferrichrome inhibits the growth of refractory pancreatic cancer cells. Int J Oncol 2020;57:721-32. [PMID: 32705165 DOI: 10.3892/ijo.2020.5096] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
199 Lundberg J, Reardon J, Blazer M, Phillips G, Bekaii-Saab T. Biweekly gemcitabine and low-dose cisplatin in the treatment of locally advanced or metastatic pancreatic cancer patients: a single institute experience. Med Oncol 2016;33:4. [PMID: 26696390 DOI: 10.1007/s12032-015-0720-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
200 Moorcraft SY, Khan K, Peckitt C, Watkins D, Rao S, Cunningham D, Chau I. FOLFIRINOX for Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma: The Royal Marsden Experience. Clinical Colorectal Cancer 2014;13:232-8. [DOI: 10.1016/j.clcc.2014.09.005] [Cited by in Crossref: 44] [Cited by in F6Publishing: 45] [Article Influence: 5.5] [Reference Citation Analysis]
201 Collins DC, Morris PG. Systemic therapy for advanced pancreatic cancer: individualising cytotoxic therapy. Expert Opinion on Pharmacotherapy 2015;16:851-61. [DOI: 10.1517/14656566.2015.1024654] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
202 Hess V, Pratsch S, Potthast S, Lee L, Winterhalder R, Widmer L, Cescato C, Lohri A, Jost L, Stillhart P, Pestalozzi B, Herrmann R. Combining gemcitabine, oxaliplatin and capecitabine (GEMOXEL) for patients with advanced pancreatic carcinoma (APC): a phase I/II trial. Ann Oncol 2010;21:2390-5. [PMID: 20444846 DOI: 10.1093/annonc/mdq242] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 1.6] [Reference Citation Analysis]
203 Li B, Gan R, Yang Q, Huang J, Chen P, Wan L, Guo C. Chinese Herbal Medicines as an Adjunctive Therapy for Unresectable Pancreatic Cancer: A Systematic Review and Meta-Analysis. Evid Based Complement Alternat Med. 2015;2015:350730. [PMID: 26681966 DOI: 10.1155/2015/350730] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
204 Fredebohm J, Wolf J, Hoheisel JD, Boettcher M. Depletion of RAD17 sensitizes pancreatic cancer cells to gemcitabine. J Cell Sci 2013;126:3380-9. [PMID: 23687379 DOI: 10.1242/jcs.124768] [Cited by in Crossref: 17] [Cited by in F6Publishing: 20] [Article Influence: 1.9] [Reference Citation Analysis]
205 Numata M, Morinaga S, Watanabe T, Tamagawa H, Yamamoto N, Shiozawa M, Nakamura Y, Kameda Y, Okawa S, Rino Y, Akaike M, Masuda M, Miyagi Y. The clinical significance of SWI/SNF complex in pancreatic cancer. Int J Oncol 2013;42:403-10. [PMID: 23229642 DOI: 10.3892/ijo.2012.1723] [Cited by in Crossref: 32] [Cited by in F6Publishing: 31] [Article Influence: 3.2] [Reference Citation Analysis]
206 O’Reilly EM, Perelshteyn A, Jarnagin WR, Schattner M, Gerdes H, Capanu M, Tang LH, LaValle J, Winston C, DeMatteo RP. A single-arm, nonrandomized phase II trial of neoadjuvant gemcitabine and oxaliplatin in patients with resectable pancreas adenocarcinoma. Ann Surg. 2014;260:142-148. [PMID: 24901360 DOI: 10.1097/sla.0000000000000251] [Cited by in Crossref: 92] [Cited by in F6Publishing: 39] [Article Influence: 11.5] [Reference Citation Analysis]
207 Ko AH, Venook AP, Bergsland EK, Kelley RK, Korn WM, Dito E, Schillinger B, Scott J, Hwang J, Tempero MA. A phase II study of bevacizumab plus erlotinib for gemcitabine-refractory metastatic pancreatic cancer. Cancer Chemother Pharmacol. 2010;66:1051-1057. [PMID: 20130876 DOI: 10.1007/s00280-010-1257-5] [Cited by in Crossref: 47] [Cited by in F6Publishing: 49] [Article Influence: 3.9] [Reference Citation Analysis]
208 Niu L, Chen J, He L, Liao M, Yuan Y, Zeng J, Li J, Zuo J, Xu K. Combination Treatment With Comprehensive Cryoablation and Immunotherapy in Metastatic Pancreatic Cancer. Pancreas 2013;42:1143-9. [DOI: 10.1097/mpa.0b013e3182965dde] [Cited by in Crossref: 49] [Cited by in F6Publishing: 31] [Article Influence: 5.4] [Reference Citation Analysis]
209 Lowery MA, O'Reilly EM. Genomics and pharmacogenomics of pancreatic adenocarcinoma. Pharmacogenomics J 2012;12:1-9. [PMID: 22186617 DOI: 10.1038/tpj.2011.52] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 0.9] [Reference Citation Analysis]
210 Deng GC, Sun DC, Zhou Q, Lv Y, Yan H, Han QL, Dai GH. Identification of DNA methylation-driven genes and construction of a nomogram to predict overall survival in pancreatic cancer. BMC Genomics 2021;22:791. [PMID: 34732125 DOI: 10.1186/s12864-021-08097-w] [Reference Citation Analysis]
211 Colloca G, Venturino A, Guarneri D. Analysis of Response-Related and Time-to-event Endpoints in Randomized Trials of Gemcitabine-Based Treatment Versus Gemcitabine Alone as First-Line Treatment of Patients With Advanced Pancreatic Cancer. Clin Colorectal Cancer 2016;15:264-76. [PMID: 26776098 DOI: 10.1016/j.clcc.2015.11.006] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
212 Wang J, Zheng R, Wang Z, Yang Y, Wang M, Zou W. Efficacy and Safety of Vinorelbine Plus Cisplatin vs. Gemcitabine Plus Cisplatin for Treatment of Metastatic Triple-Negative Breast Cancer After Failure with Anthracyclines and Taxanes. Med Sci Monit 2017;23:4657-64. [PMID: 28957036 DOI: 10.12659/msm.905300] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
213 Von Hoff DD, Ramanathan RK, Borad MJ, Laheru DA, Smith LS, Wood TE, Korn RL, Desai N, Trieu V, Iglesias JL. Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial. J Clin Oncol. 2011;29:4548-4554. [PMID: 21969517 DOI: 10.1200/jco.2011.36.5742] [Cited by in Crossref: 692] [Cited by in F6Publishing: 389] [Article Influence: 62.9] [Reference Citation Analysis]
214 Soo RA, Yong WP, Innocenti F. Systemic therapies for pancreatic cancer--the role of pharmacogenetics. Curr Drug Targets. 2012;13:811-828. [PMID: 22458528 DOI: 10.1016/j.pestbp.2011.02.012.investigations] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
215 Giuliani J, Bonetti A. FOLFIRINOX is a cost-effective combination chemotherapy in first-line for advanced pancreatic Cancer. Pancreatology 2019;19:325-30. [DOI: 10.1016/j.pan.2019.01.014] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
216 Hashmi A, Kozick Z, Fluck M, Hunsinger MA, Wild J, Arora TK, Shabahang MM, Blansfield JA. Neoadjuvant versus Adjuvant Chemotherapy for Resectable Pancreatic Adenocarcinoma: A National Cancer Database Analysis. The American Surgeon 2018;84:1439-45. [DOI: 10.1177/000313481808400946] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
217 Khalil MA, Qiao W, Carlson P, George B, Javle M, Overman M, Varadhachary G, Wolff RA, Abbruzzese JL, Fogelman DR. The addition of erlotinib to gemcitabine and cisplatin does not appear to improve median survival in metastatic pancreatic cancer. Invest New Drugs. 2013;31:1375-1383. [PMID: 23645398 DOI: 10.1007/s10637-013-9967-2] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
218 Ko AH, Espinoza AM, Jones KA, Venook AP, Bergsland EK, Kelley RK, Dito E, Ong A, Hanover CS, Coakley FV, Tempero MA. Optimizing the Administration of Fixed-Dose Rate Gemcitabine Plus Capecitabine Using an Alternating-week Schedule: A Dose Finding and Early Efficacy Study in Advanced Pancreatic and Biliary Carcinomas. American Journal of Clinical Oncology 2012;35:411-7. [DOI: 10.1097/coc.0b013e3182185888] [Cited by in Crossref: 9] [Cited by in F6Publishing: 2] [Article Influence: 0.9] [Reference Citation Analysis]
219 Varghese AM, Lowery MA, Yu KH, O'Reilly EM. Current management and future directions in metastatic pancreatic adenocarcinoma. Cancer 2016;122:3765-75. [PMID: 27649047 DOI: 10.1002/cncr.30342] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.2] [Reference Citation Analysis]
220 Wolfgang CL, Herman JM, Laheru DA, Klein AP, Erdek MA, Fishman EK, Hruban RH. Recent progress in pancreatic cancer. CA Cancer J Clin. 2013;63:318-348. [PMID: 23856911 DOI: 10.1002/caac.21190] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
221 Tabernero J, Macarulla T. Changing the paradigm in conducting randomized clinical studies in advanced pancreatic cancer: an opportunity for better clinical development. J Clin Oncol. 2009;27:5487-5491. [PMID: 19858387 DOI: 10.1200/jco.2009.23.3098] [Cited by in Crossref: 20] [Cited by in F6Publishing: 10] [Article Influence: 1.5] [Reference Citation Analysis]
222 Rachagani S, Senapati S, Chakraborty S, Ponnusamy MP, Kumar S, Smith LM, Jain M, Batra SK. Activated KrasG¹²D is associated with invasion and metastasis of pancreatic cancer cells through inhibition of E-cadherin. Br J Cancer. 2011;104:1038-1048. [PMID: 21364589 DOI: 10.1038/bjc.2011.31] [Cited by in Crossref: 48] [Cited by in F6Publishing: 54] [Article Influence: 4.4] [Reference Citation Analysis]
223 Li W, Wang Y, Kellner DB, Xu L, Mai L. Efficacy of cytokine-induced killer cells in the treatment of elderly patients with metastatic pancreatic adenocarcinoma. Cent Eur J Immunol 2015;40:188-93. [PMID: 26557033 DOI: 10.5114/ceji.2015.52833] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.1] [Reference Citation Analysis]
224 Sclafani F, Iyer R, Cunningham D, Starling N. Management of metastatic pancreatic cancer: Current treatment options and potential new therapeutic targets. Crit Rev Oncol Hematol 2015;95:318-36. [PMID: 25921418 DOI: 10.1016/j.critrevonc.2015.03.008] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 2.1] [Reference Citation Analysis]
225 Larbouret C, Robert B, Bascoul-Mollevi C, Penault-Llorca F, Ho-Pun-Cheung A, Morisseau S, Navarro-Teulon I, Mach JP, Pèlegrin A, Azria D. Combined cetuximab and trastuzumab are superior to gemcitabine in the treatment of human pancreatic carcinoma xenografts. Ann Oncol. 2010;21:98-103. [PMID: 19889608 DOI: 10.1093/annonc/mdp496] [Cited by in Crossref: 31] [Cited by in F6Publishing: 31] [Article Influence: 2.4] [Reference Citation Analysis]
226 Hunter KU, Feng FY, Griffith KA, Francis IR, Lawrence TS, Desai S, Murphy JD, Zalupski MM, Ben-josef E. Radiation Therapy With Full-Dose Gemcitabine and Oxaliplatin for Unresectable Pancreatic Cancer. International Journal of Radiation Oncology*Biology*Physics 2012;83:921-6. [DOI: 10.1016/j.ijrobp.2011.08.022] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
227 Chin V, Nagrial A, Sjoquist K, O'Connor CA, Chantrill L, Biankin AV, Scholten RJ, Yip D. Chemotherapy and radiotherapy for advanced pancreatic cancer. Cochrane Database Syst Rev 2018;3:CD011044. [PMID: 29557103 DOI: 10.1002/14651858.CD011044.pub2] [Cited by in Crossref: 22] [Cited by in F6Publishing: 30] [Article Influence: 5.5] [Reference Citation Analysis]
228 Bayraktar S, Bayraktar UD, Rocha-Lima CM. Recent developments in palliative chemotherapy for locally advanced and metastatic pancreas cancer. World J Gastroenterol 2010; 16(6): 673-682 [PMID: 20135714 DOI: 10.3748/wjg.v16.i6.673] [Cited by in CrossRef: 40] [Cited by in F6Publishing: 38] [Article Influence: 3.3] [Reference Citation Analysis]
229 Gresham GK, Wells GA, Gill S, Cameron C, Jonker DJ. Chemotherapy regimens for advanced pancreatic cancer: a systematic review and network meta-analysis. BMC Cancer 2014;14:471. [PMID: 24972449 DOI: 10.1186/1471-2407-14-471] [Cited by in Crossref: 77] [Cited by in F6Publishing: 70] [Article Influence: 9.6] [Reference Citation Analysis]
230 Jones RM, Kotsantis P, Stewart GS, Groth P, Petermann E. BRCA2 and RAD51 promote double-strand break formation and cell death in response to gemcitabine. Mol Cancer Ther 2014;13:2412-21. [PMID: 25053826 DOI: 10.1158/1535-7163.MCT-13-0862] [Cited by in Crossref: 28] [Cited by in F6Publishing: 21] [Article Influence: 3.5] [Reference Citation Analysis]
231 Hua Y, Chen H, Wang L, Wang F, Wang P, Ning Z, Li Y, Liu L, Chen Z, Meng Z. Low serum miR-373 predicts poor prognosis in patients with pancreatic cancer. Cancer Biomark 2017;20:95-100. [PMID: 28759959 DOI: 10.3233/CBM-170231] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 3.8] [Reference Citation Analysis]
232 Hyde AJ, Nassabein R, AlShareef A, Armstrong D, Babak S, Berry S, Bossé D, Chen E, Colwell B, Essery C, Goel R, Goodwin R, Gray S, Hammad N, Jeyakuymar A, Jonker D, Karanicolas P, Lamond N, Letourneau R, Michael J, Patil N, Powell E, Ramjeesingh R, Saliba W, Singh R, Snow S, Stuckless T, Tadros S, Tehfé M, Thana M, Thirlwell M, Vickers M, Virik K, Welch S, Asmis T. Eastern Canadian Gastrointestinal Cancer Consensus Conference 2018. Curr Oncol 2019;26:e665-81. [PMID: 31708660 DOI: 10.3747/co.26.5193] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
233 Harder J, Ihorst G, Heinemann V, Hofheinz R, Moehler M, Buechler P, Kloeppel G, Röcken C, Bitzer M, Boeck S, Endlicher E, Reinacher-Schick A, Schmoor C, Geissler M. Multicentre phase II trial of trastuzumab and capecitabine in patients with HER2 overexpressing metastatic pancreatic cancer. Br J Cancer 2012;106:1033-8. [PMID: 22374460 DOI: 10.1038/bjc.2012.18] [Cited by in Crossref: 105] [Cited by in F6Publishing: 103] [Article Influence: 10.5] [Reference Citation Analysis]
234 Lee J, Lee J, Kim M, Kim JH. Fermented Extraction of Citrus unshiu Peel Inhibits Viability and Migration of Human Pancreatic Cancers. J Med Food 2018;21:5-12. [PMID: 29346059 DOI: 10.1089/jmf.2017.3984] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 2.8] [Reference Citation Analysis]
235 Hidalgo M, Abad A, Aranda E, Díez L, Feliu J, Gómez C, Irigoyen A, López R, Rivera F, Rubio C, Sastre J, Tabernero J, Díaz-Rubio E. Consensus on the treatment of pancreatic cancer in Spain. Clin Transl Oncol 2009;11:290-301. [PMID: 19451062 DOI: 10.1007/s12094-009-0357-3] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
236 Boeck S, Vehling-Kaiser U, Waldschmidt D, Kettner E, Märten A, Winkelmann C, Klein S, Kojouharoff G, Gauler T, Fischer von Weikersthal L, Clemens MR, Geissler M, Greten TF, Hegewisch-Becker S, Neugebauer S, Heinemann V. Erlotinib 150 mg daily plus chemotherapy in advanced pancreatic cancer: an interim safety analysis of a multicenter, randomized, cross-over phase III trial of the 'Arbeitsgemeinschaft Internistische Onkologie'. Anticancer Drugs 2010;21:94-100. [PMID: 19770635 DOI: 10.1097/CAD.0b013e32833123ed] [Cited by in Crossref: 20] [Cited by in F6Publishing: 7] [Article Influence: 1.7] [Reference Citation Analysis]
237 Ko AH. Progress in the treatment of metastatic pancreatic cancer and the search for next opportunities. J Clin Oncol. 2015;33:1779-1786. [PMID: 25918299 DOI: 10.1200/jco.2014.59.7625] [Cited by in Crossref: 49] [Cited by in F6Publishing: 30] [Article Influence: 7.0] [Reference Citation Analysis]
238 Löhr JM, Haas SL, Bechstein WO, Bodoky G, Cwiertka K, Fischbach W, Fölsch UR, Jäger D, Osinsky D, Prausova J. Cationic liposomal paclitaxel plus gemcitabine or gemcitabine alone in patients with advanced pancreatic cancer: a randomized controlled phase II trial. Ann Oncol. 2012;23:1214-1222. [PMID: 21896540 DOI: 10.1093/annonc/mdr379] [Cited by in Crossref: 63] [Cited by in F6Publishing: 56] [Article Influence: 5.7] [Reference Citation Analysis]
239 Hou J, Wang L. FKBP5 as a selection biomarker for gemcitabine and Akt inhibitors in treatment of pancreatic cancer. PLoS One 2012;7:e36252. [PMID: 22590527 DOI: 10.1371/journal.pone.0036252] [Cited by in Crossref: 29] [Cited by in F6Publishing: 32] [Article Influence: 2.9] [Reference Citation Analysis]
240 Kruger S, Boeck S, Heinemann V, Laubender RP, Vehling-kaiser U, Waldschmidt D, Kettner E, Märten A, Winkelmann C, Klein S, Kojouharoff G, Gauler TC, Fischer von Weikersthal L, Clemens MR, Geissler M, Greten TF, Hegewisch-becker S, Modest DP, Stintzing S, Haas M. Impact of hand-foot skin reaction on treatment outcome in patients receiving capecitabine plus erlotinib for advanced pancreatic cancer: A subgroup analysis from AIO-PK0104. Acta Oncologica 2015;54:993-1000. [DOI: 10.3109/0284186x.2015.1034877] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
241 Lutz MP, Pourebrahim S. [Pancreatic carcinoma]. Internist (Berl) 2008;49:1079-86; quiz 1087. [PMID: 18677456 DOI: 10.1007/s00108-008-2203-z] [Cited by in Crossref: 2] [Article Influence: 0.1] [Reference Citation Analysis]
242 Pelzer U, Arnold D, Reitzig P, Herrenberger J, Korsten FW, Kindler M, Stieler J, Dörken B, Riess H, Oettle H. First-line treatment of pancreatic cancer patients with the combination of 5-fluorouracil/folinic acid plus gemcitabine: a multicenter phase II trial by the CONKO-study group. Cancer Chemother Pharmacol 2011;68:1173-8. [PMID: 21400239 DOI: 10.1007/s00280-011-1602-3] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
243 Kristensen A, Vagnildhaug OM, Grønberg BH, Kaasa S, Laird B, Solheim TS. Does chemotherapy improve health-related quality of life in advanced pancreatic cancer? A systematic review. Crit Rev Oncol Hematol 2016;99:286-98. [PMID: 26819138 DOI: 10.1016/j.critrevonc.2016.01.006] [Cited by in Crossref: 22] [Cited by in F6Publishing: 27] [Article Influence: 3.7] [Reference Citation Analysis]
244 Mantripragada KC, Safran H. Optimizing initial chemotherapy for metastatic pancreatic cancer. Future Oncol 2016;12:1125-33. [PMID: 26939741 DOI: 10.2217/fon-2015-0006] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
245 James E, Waldron-Lynch MG, Saif MW. Prolonged survival in a patient with BRCA2 associated metastatic pancreatic cancer after exposure to camptothecin: a case report and review of literature. Anticancer Drugs. 2009;20:634-638. [PMID: 19433978 DOI: 10.1097/cad.0b013e32832b511e] [Cited by in Crossref: 34] [Cited by in F6Publishing: 16] [Article Influence: 2.6] [Reference Citation Analysis]
246 Tanaka T, Sho M, Nishiofuku H, Sakaguchi H, Inaba Y, Nakajima Y, Kichikaiwa K. Unresectable Pancreatic Cancer: Arterial Embolization to Achieve a Single Blood Supply for Intraarterial Infusion of 5-Fluorouracil and Full-Dose IV Gemcitabine. American Journal of Roentgenology 2012;198:1445-52. [DOI: 10.2214/ajr.11.8008] [Cited by in Crossref: 12] [Cited by in F6Publishing: 3] [Article Influence: 1.2] [Reference Citation Analysis]
247 Hu HF, Ye Z, Qin Y, Xu XW, Yu XJ, Zhuo QF, Ji SR. Mutations in key driver genes of pancreatic cancer: molecularly targeted therapies and other clinical implications. Acta Pharmacol Sin 2021. [PMID: 33574569 DOI: 10.1038/s41401-020-00584-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
248 Mross K, Dittrich C, Aulitzky WE, Strumberg D, Schutte J, Schmid RM, Hollerbach S, Merger M, Munzert G, Fleischer F, Scheulen ME. A randomised phase II trial of the Polo-like kinase inhibitor BI 2536 in chemo-naïve patients with unresectable exocrine adenocarcinoma of the pancreas - a study within the Central European Society Anticancer Drug Research (CESAR) collaborative network. Br J Cancer 2012;107:280-6. [PMID: 22699824 DOI: 10.1038/bjc.2012.257] [Cited by in Crossref: 45] [Cited by in F6Publishing: 41] [Article Influence: 4.5] [Reference Citation Analysis]
249 Rivera F, López-Tarruella S, Vega-Villegas ME, Salcedo M. Treatment of advanced pancreatic cancer: from gemcitabine single agent to combinations and targeted therapy. Cancer Treat Rev. 2009;35:335-339. [PMID: 19131170 DOI: 10.1016/j.ctrv.2008.11.007] [Cited by in Crossref: 73] [Cited by in F6Publishing: 73] [Article Influence: 5.6] [Reference Citation Analysis]
250 Liu Y, Huang QK, Hong WD, Wu JM, Sun XC. The addition of S-1 to gemcitabine-based chemotherapy improves survival with increased toxicity for patients with advanced pancreatic cancer: combined meta-analysis of efficacy and safety profile. Clin Res Hepatol Gastroenterol 2015;39:254-60. [PMID: 25304193 DOI: 10.1016/j.clinre.2014.08.012] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
251 Hirooka Y, Kawashima H, Ohno E, Ishikawa T, Kamigaki T, Goto S, Takahara M, Goto H. Comprehensive immunotherapy combined with intratumoral injection of zoledronate-pulsed dendritic cells, intravenous adoptive activated T lymphocyte and gemcitabine in unresectable locally advanced pancreatic carcinoma: a phase I/II trial. Oncotarget 2018;9:2838-47. [PMID: 29416816 DOI: 10.18632/oncotarget.22974] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 2.6] [Reference Citation Analysis]
252 Sun C, Ansari D, Andersson R, Wu DQ. Does gemcitabine-based combination therapy improve the prognosis of unresectable pancreatic cancer? World J Gastroenterol 2012; 18(35): 4944-4958 [PMID: 23002368 DOI: 10.3748/wjg.v18.i35.4944] [Cited by in CrossRef: 47] [Cited by in F6Publishing: 48] [Article Influence: 4.7] [Reference Citation Analysis]
253 Zhu M, Zhang Q, Wang X, Kang L, Yang Y, Liu Y, Yang L, Li J, Yang L, Liu J, Li Y, Zu L, Shen Y, Qi Z. Metformin potentiates anti-tumor effect of resveratrol on pancreatic cancer by down-regulation of VEGF-B signaling pathway. Oncotarget 2016;7:84190-200. [PMID: 27705937 DOI: 10.18632/oncotarget.12391] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 4.0] [Reference Citation Analysis]
254 Paulson AS, Tran Cao HS, Tempero MA, Lowy AM. Therapeutic advances in pancreatic cancer. Gastroenterology. 2013;144:1316-1326. [PMID: 23622141 DOI: 10.1053/j.gastro.2013.01.078] [Cited by in Crossref: 188] [Cited by in F6Publishing: 181] [Article Influence: 20.9] [Reference Citation Analysis]
255 Lee JY, Song SY, Park JY. Notch pathway activation is associated with pancreatic cancer treatment failure. Pancreatology 2014;14:48-53. [PMID: 24555978 DOI: 10.1016/j.pan.2013.11.011] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 2.3] [Reference Citation Analysis]
256 Pericay Pijaume C, Escudero Emperador P, Bastús Piulats R, Campos Cervera JM, Esquerdo Galiana G, Gallén Castillo M, Alfaro Gamero J, Dotor Navarro E, Pisa Gatell A, Guasch Jordán I, Saigí Grau E; ACROSS group. Open-label trial on efficacy and security of treatment with gemcitabine and oral modulation with tegafur and levofolinic acid (GEMTG) in patients with advanced pancreatic cancer. Clin Transl Oncol 2011;13:61-6. [PMID: 21239357 DOI: 10.1007/s12094-011-0618-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
257 Valsecchi ME, Holdbrook T, Leiby BE, Pequignot E, Littman SJ, Yeo CJ, Brody JR, Witkiewicz AK. Is there a role for the quantification of RRM1 and ERCC1 expression in pancreatic ductal adenocarcinoma? BMC Cancer. 2012;12:104. [PMID: 22436573 DOI: 10.1186/1471-2407-12-104] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 2.1] [Reference Citation Analysis]
258 Connor AA, Gallinger S. Hereditary Pancreatic Cancer Syndromes. Surg Oncol Clin N Am. 2015;24:733-764. [PMID: 26363539 DOI: 10.1016/j.soc.2015.06.007] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 3.3] [Reference Citation Analysis]
259 Garajová I, Le Large TY, Frampton AE, Rolfo C, Voortman J, Giovannetti E. Molecular mechanisms underlying the role of microRNAs in the chemoresistance of pancreatic cancer. Biomed Res Int. 2014;2014:678401. [PMID: 25250326 DOI: 10.1155/2014/678401] [Cited by in Crossref: 25] [Cited by in F6Publishing: 27] [Article Influence: 3.1] [Reference Citation Analysis]
260 Hagmann W, Jesnowski R, Löhr JM. Interdependence of gemcitabine treatment, transporter expression, and resistance in human pancreatic carcinoma cells. Neoplasia 2010;12:740-7. [PMID: 20824050 DOI: 10.1593/neo.10576] [Cited by in Crossref: 75] [Cited by in F6Publishing: 77] [Article Influence: 6.8] [Reference Citation Analysis]
261 Hu H, Gu Y, Qian Y, Hu B, Zhu C, Wang G, Li J. DNA-PKcs is important for Akt activation and gemcitabine resistance in PANC-1 pancreatic cancer cells. Biochem Biophys Res Commun. 2014;452:106-111. [PMID: 25152407 DOI: 10.1016/j.bbrc.2014.08.059] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 2.4] [Reference Citation Analysis]
262 Werner J, Combs SE, Springfeld C, Hartwig W, Hackert T, Büchler MW. Advanced-stage pancreatic cancer: therapy options. Nat Rev Clin Oncol. 2013;10:323-333. [PMID: 23629472 DOI: 10.1038/nrclinonc.2013.66] [Cited by in Crossref: 133] [Cited by in F6Publishing: 124] [Article Influence: 14.8] [Reference Citation Analysis]
263 Combs S, Habermehl D, Werner J, Büchler M, Debus J. Strategien für präoperatives Downsizing bei inoperablem Pankreaskarzinom. Chirurg 2011;82:981-8. [DOI: 10.1007/s00104-011-2129-1] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
264 Buc E, Couvelard A, Kwiatkowski F, Dokmak S, Ruszniewski P, Hammel P, Belghiti J, Sauvanet A. Adenocarcinoma of the pancreas: Does prognosis depend on mode of lymph node invasion? European Journal of Surgical Oncology (EJSO) 2014;40:1578-85. [DOI: 10.1016/j.ejso.2014.04.012] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 3.0] [Reference Citation Analysis]
265 O Kane GM, Knox JJ. Locally advanced pancreatic cancer: An emerging entity. Curr Probl Cancer 2018;42:12-25. [PMID: 29153290 DOI: 10.1016/j.currproblcancer.2017.10.006] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
266 Karakas Y, Lacin S, Yalcin S. Recent advances in the management of pancreatic adenocarcinoma. Expert Review of Anticancer Therapy 2018;18:51-62. [DOI: 10.1080/14737140.2018.1403319] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
267 Huang ZM, Pan CC, Wu PH, Zhao M, Li W, Huang ZL, Yi RY. Efficacy of minimally invasive therapies on unresectable pancreatic cancer. Chin J Cancer. 2013;32:334-341. [PMID: 22958741 DOI: 10.5732/cjc.012.10093.epub] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
268 Huang ZM, Pan CC, Wu PH, Zhao M, Li W, Huang ZL, Yi RY. Efficacy of minimally invasive therapies on unresectable pancreatic cancer. Chin J Cancer. 2013;32:334-341. [PMID: 22958741 DOI: 10.5732/cjc.012.10093] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
269 Siddiqui NS, Godara A, Byrne MM, Saif MW. Capecitabine for the treatment of pancreatic cancer. Expert Opin Pharmacother 2019;20:399-409. [PMID: 30649964 DOI: 10.1080/14656566.2018.1560422] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]
270 Xue P, Zhu L, Wan Z, Huang W, Li N, Chen D, Hu J, Yang H, Wang L. A prognostic index model to predict the clinical outcomes for advanced pancreatic cancer patients following palliative chemotherapy. J Cancer Res Clin Oncol 2015;141:1653-60. [PMID: 25792009 DOI: 10.1007/s00432-015-1953-y] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.7] [Reference Citation Analysis]
271 Dang A, Chidirala S, Veeranki P, Vallish BN. A Critical Overview of Systematic Reviews of Chemotherapy for Advanced and Locally Advanced Pancreatic Cancer using both AMSTAR2 and ROBIS as Quality Assessment Tools. Rev Recent Clin Trials 2021;16:180-92. [PMID: 32875987 DOI: 10.2174/1574887115666200902111510] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
272 Waddell N, Pajic M, Patch AM, Chang DK, Kassahn KS, Bailey P, Johns AL, Miller D, Nones K, Quek K. Whole genomes redefine the mutational landscape of pancreatic cancer. Nature. 2015;518:495-501. [PMID: 25719666 DOI: 10.1038/nature14169] [Cited by in Crossref: 1379] [Cited by in F6Publishing: 1238] [Article Influence: 197.0] [Reference Citation Analysis]